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ABSTRACT
LUNG AND COLON CANCER CHEMOPREVENTION BY
POLYMETHOXYFLAVONES
FEBRUARY 2017
MINGYUE SONG,
B.S., NORTHWEST A&F UNIVERSTIY, YANGLING, CHINA
M.S., NORTHWEST A&F UNIVERSTIY, YANGLING, CHINA
Ph.D., UNIVERSTIY OF MASSACHUSETTS AMHERST
Directed by: Professor Hang Xiao
Cancer has been a leading cause of morbidity and mortality worldwide and
characterized by the uncontrolled cell proliferation and an absence of cell death.
Polymethoxyflavones (PMFs) is a unique class of flavonoids that almost exclusively
found in the peel of citrus fruit. Studies have showed that PMFs exhibited numerous
health promoting effects, including anti-carcinogenic and anti-inflammatory ones.
Nobiletin (5,6,7,8,3’,4’-hexamethyoxflavone, NBT) is a major citrus flavonoid and has
been the most studied PMFs for its potential health benefits. 5-Demethylnobiletin
(5-hydroxy-6,7,8,3’,4’-pentamethoxyflavone, 5DN) is a unique flavonoid found in citrus
fruits with potential chemopreventive effects against human cancers.
In this dissertation, we first determined the inhibitory effects of 5DN and its two
major metabolites in the in the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK)-induced lung tumorigenesis mouse model as well as in human and mouse lung
cancer cell models. In NNK-treated female A/J mice, dietary administration of 5DN
significantly

decreased

both

lung

tumor

multiplicity

and

tumor

volume.

Immunohistochemical analysis showed strong anti-proliferative effect of 5DN in lung
tumors. Two major metabolites of 5DN, named 5,3ʹ-didemethylnobiletin (M1) and
5,4ʹ-didemethylnobiletin (M2), were found in the lung tissue of 5DN-fed mice. Cell
culture studies demonstrated that 5DN, M1 and M2 significantly inhibited the growth of
human and mouse lung cancer cells by causing cell cycle arrest, inducing apoptosis and
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modulating key signaling proteins related with cell proliferation and cell death.
Interestingly, the metabolites of 5DN, especially M1 produced much stronger inhibitory
effects on both human and mouse lung cancer cells than those produced by 5DN itself.
Combination of different bioactive agents may produce enhanced bioactive effects
due to their synergistic interactions. Our previous study had demonstrated that the
combination of NBT and atorvastatin (ATST, a cholesterol-lowering drug) exerted strong
synergistic inhibition on lung cancer cells growth. Herein we investigated the in vivo
efficacy and possible synergistic inhibitory effect of NBT/ATST combination in
NNK-induced lung tumorigenesis mouse model. We found that NBT/ATST half dose
combination synergistically produced much stronger inhibition on lung tumor
multiplicity and tumor burden than those produced by individual treatment with NBT or
ATST at full dose. The inhibition was associated with suppressed cell proliferation and
enhanced apoptosis in adenoma as determined by immunohistochemistry.
Chronic inflammation is implicated as a risk factor for many diseases including
colorectal cancer. Growing evidence has demonstrated that certain dietary agents can
inhibit inflammation and to prevent the progression of cancer. 5DN has been reported to
have anti-inflammatory and anti-carcinogenic activities in cell culture studies previously.
Therefore, we demonstrated that dietary 5DN significantly inhibit tumor incidence,
multiplicity and tumor burden in AOM/DSS-induced colon carcinogenesis mice model.
The inhibitory effect of 5DN was closely by it colonic metabolites, namely M1, M2, and
M3. Cell culture study indicated that the metabolites, especially M1, had more potent
activity in inhibiting the growth of HCT116 human colon cancer cell, when compared to
5DN. And the inhibition was associated with the induction of cell cycle arrest and
apoptosis, as well as the modulation the expression of key signaling protein that related to
cell proliferation and apoptosis.
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CHAPTER 1
INTRODUCTION
Cancer is a group of diseases that characterized by uncontrolled cell division,
replicative immortality and resistance to cell death(1). For the year 2016, it was estimated
that 1,685,210 new cancer cases will be diagnosed and approximately 595,690 cancer
deaths will occur in the United States(2). Traditional cancer therapies (Surgery,
radiotherapy, chemotherapy) have been demonstrated to show adverse side effects during
and after treatments, increasing rate of unsuccessful results including cancer recurrence,
and expensive cost particularly if long-term treatment s are necessary. Taking all these
facts together, there is an urgent need for novel strategies for cancer treatments and
prevention.
It is estimated that about one-third of incident cancer that occur in the US are related
to life style factor such as poor nutrition, excess alcohol consumption, physical inactivity
and excess weight, and therefore can be prevented(3,4). Besides modifying lifestyle
factors, another promising approach is to decrease of the progress of cancer through
administration of natural products with chemopreventive properties, such as herb, fruits,
and vegetables. Epidemiological studies have documented that higher vegetables and
fruits consumption may reduce the risk of carcinogenesis. Chemoprevention is defined as
the selectively utilization of dietary components or their analogs to inhibit, delay, or
reverse the process of carcinogenesis(5). Chemoprevention has showed to be the
cost-effective alternative to general cancer therapies due to no or little unwanted side
effects. Flavonoids have been displayed to ameliorate human health. To date, More than
25,000 different phytochemicals have been reported to show potential inhibitory effects
against

multiple

cancers(6).

Almost

exclusively

found

in

citrus

fruit,

polymethoxyflavones (PMFs) is a unique class of flavonoid that exert a broad spectrum
of biological activities(7–9). Nobiletin (NBT), a major citrus PMF existed in orange peel
extract, have demonstrated a wide range of health beneficial bioactivities(10–14).
5-Demethylnobiletin (5DN) is one of the most abundant PMFs found in orange peel, and
it can be formed through the auto-hydrolysis of nobiletin during long-term storage(15).
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Recently, 5DN has been demonstrated to possess more potent inhibitory effects on the
growth of various cancer cells compared with its PMF counterpart nobiletin(9,16),
suggesting a pivotal role of the hydroxyl group at the 5-position in the growth inhibition
of cancer cells.
Atorvastatin calcium (Lipitor, ATST) is one of the most prescribed drugs in the
United States due to its cholesterol-lowering effect. Recently, growing studies have
reported that statins drugs including ATST exerted some other health-benefit effects
rather than lowering cholesterol. These effects could be attributed to the inhibition of
3-hydroxy-methylgluraryl CoA reductase by the statins. Accumulating studies revealed
that ATST exhibit anticancer effect both in vitro and in vivo(17,18).
Combination treatments with two or more agents at lower doses that targeting
different molecular targets may produce enhanced biological activities than those
produced by each individual agent at higher doses. The enhanced efficacy by the
combination, which is due to the synergistic interaction, can minimize the adverse side
effects possibly resulted from the long-term and high dose use of individual treatment.
Growing evidence has suggested that the combination of pharmaceutical drugs and
dietary bioactive agents may show potential health benefits including cancer prevention.
ATST is reported to be a competent candidate in combination strategies with multiple
dietary components for cancer prevention both in vitro and in vivo studies(19–22).
Biotransformation can greatly determine the biological activities of dietary bioactive
compounds(23). Because the metabolites generated in the body after digestion may show
various bioactivities. Moreover, the levels of the metabolites may be higher than their
parent compound in certain tissues. Therefore, the metabolites, rather than the parent
compound, may dominantly contribute to the biological effects. A wealth of studies has
suggested that some metabolites of PMFs exhibited much stronger biological activities
than those of their parent compounds(24,25).
Taking all these together, our long-term goal is to improve lung and colon cancer
prevention strategy by utilizing dietary components. To achieve that goal, the overall
objective of this project is to develop dietary-based chemoprevention strategies targeting
lung and colon carcinogenesis by utilizing PMFs. Moreover, we will investigate the
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potential synergistic effects of combing PMFs and ATST on lung cancer inhibition. Our
central hypothesis is that PMFs and their metabolites are able to inhibit lung and colon
carcinogenesis. Also, by combining with ATST, PMFs will exert synergistic
chemopreventive effects on lung and colon carcinogenesis. Our hypothesis has been
formulated based on the preliminary results from our and others, which had showed
PMFs produced potent anticancer and anti-inflammatory effects in various cancers such
as lung, colon and breast cancers, and enhanced growth inhibition on cancer cells when
combined with ATST.
In order to test our central hypothesis and to achiever our objective, we plan to
pursue these following specific aims:
1.

Determine the inhibitory effects of 5DN and its metabolites on lung
carcinogenesis.

A

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone

(NNK)-induced lung tumorigenesis mouse model will be developed to test
the

antitumor

efficacy

of

5DN

in

vivo.

Histological

and

immunohistochemical analysis will be performed to evaluate the lung tumor
formation. The level of metabolites of 5DN in lung tissue will be determined
by HPLC method. The in vitro anticancer effects of 5DN and its metabolites
and possible mechanisms underling will be investigate in both human and
mouse cancer cells.

We anticipate observing potent inhibition on lung

carcinogenesis by 5DN.
2.

Determine the potential synergistic inhibition of nobiletin (NBT) and
atorvastatin (ATST) in combination on lung carcinogenesis. A
NNK-induced lung tumorigenesis mouse model will be used again to
evaluate the in vivo inhibitory effects of NBT, ATST, and their half-dose
combination on lung cancer. Isobologram analysis will be performed to
determine the interaction between NBT and ATST on inhibition of lung
tumor formation. We expect to observe the synergistic effect of NBT/ATST
combination on lung carcinogenesis.

3.

Determine the chemopreventive effects of 5DN and its colonic metabolites
on colon carcinogenesis. An azoxymethane (AOM)-initiated and dextran

3

sulfate

sodium

(DSS)-promoted

inflammation-associated

colon

carcinogenesis mouse model will be used to evaluate the inhibitory efficacy
of 5DN in vivo. Histological and immunohistochemical evaluation will be
performed assess the colon tumor formation on colon tissue of
AOM/DSS-treated mice. Colonic mucosa samples will be subjects to
immunoblotting, ELISA and qRT-PCR analysis to investigate the
mechanism of action of 5DN on colon carcinogenesis. HPLC analysis will
be performed to determine the levels of 5DN and its metabolites in colon
tissue. The in vitro anticancer effects of 5DN and its metabolites will be test
on human colon cancer cells culture model. It is our expectation that 5DN
and its metabolites will significantly inhibit inflammation-associated colon
carcinogenesis.
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CHAPTER 2

LITERATURE REVIEW

2.1 Overview of colorectal and lung cancer
At present, cancer is regarded as one of the most fatal health problem in US and
worldwide. According to estimates of American Cancer Society, cancer is the second
most general cause of mortality in the US, exceeded only by heart disease(2). For the
year 2016, it is estimated that a total of 1,685,210 new cancer cases will be diagnosed in
the United States and approximately 595,690 cancer-related deaths will occur.
Among different cancers, Lung cancer is the leading cause of cancer-related mortally in
both men and women. Studies and human trials on the prevention and treatment of lung
cancer have not produced promising results. The 5-year survival rate of lung cancer
patients is still below 19%, which is significantly lower than many other leading cancer
sites(26). Lung cancer can be categorized into small cell lung cancer (SCLC), and
non-small cell lung cancer (NSCLC). NSCLC is further categorized into three major
histological types: adenocarcinoma, large cell carcinoma, and squamous cell
carcinoma(27). Tobacco use represents the leading risk factor for all lung cancer types.
Generally, about 85%-90% of lung cancer cases are caused by cigarette smoking(28).
Studies have showed that compared with a lifetime non-smoker, there is an approximate
20-fold increase in the risk of developing lung cancer for a lifetime smoker(29).
Colorectal cancer (CRC) remains the third most common cause of cancer death in
the United States and the fourth globally with a rising incidence, which is associated with
economic

development

and

adoption

of

an

affluent

diet

and

lifestyle(30).

Epidemiological studies have suggested that colorectal cancer is closely related with
inherited cancer predisposition syndromes, and other factors such as obesity, smoking,
environmental carcinogens, alcohol consumption, high fat diet, inadequate intake of
vegetable, fruits and dietary fiber, and lack of physical exercise(31). Accumulating
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evidence in experimental models and humans implicates that inflammation as a risk
factor for colorectal carcinogenesis because of their promotive effects on proliferation of
malignant cells, angiogenesis and tumor metastasis(17). Patients with inflammatory
bowel disease (IBD) such Cohn’s disease and ulcerative colitis have much higher risk of
developing CRC compared to the healthy people.
2.2 Chemoprevention

2.2.1 Introduction to chemoprevention
An association between diet and disease ha persisted since early in the history of
medicine. The beneficial activities of fruits and vegetables have been attributed to the
high content of bioactive compounds that are non-nutrient constituents commonly present
in food(32). Studies have suggested that these bioactive compounds play important role
in the prevention of chronic diseases, such like cancer, diabetes and hypercholestermia. It
has been estimated that more than two-thirds of cancer occurrence could be prevented via
appropriated lifestyle modification, such as consuming healthy diet, maintain of body
weight. Richard et.al have reported that 10-70% (average 35%) of human cancer
mortality is attributed to diet(33). Vegetables and fruits contain fiber, vitamins, minerals
and various bioactive compounds, such as carotenoids, flavonoids, indoles and sterols, all
of which could account for these protective effects.
Chemoprevention is defined as the use of dietary bioactive components and/or their
synthetic analogs for intervention to reverse, suppress, or prevent the process of
carcinogenesis(34). Accumulating evidence from population as well as laboratory studies
showed an inverse relationship between regular consumption of fruit and vegetables and
the risk of specific cancers. And this can be attributed to the bioactive components
present in these fruit and vegetables. Chemoprevention by phytochemicals is now
considered to be an inexpensive, readily applicable, acceptable and accessible approach
to cancer prevention and management.
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2.2.2 Chemoprevention by dietary component
To date, more than 250 population-based studies (case-control and cohort studies)
indicate that people who eat about five servings of fruit and vegetables daily can reduce
50% risk of developing cancer, especially cancers related to digestive and respiratory
tracts, when compared to those who eat fewer than two servings(5). Vegetables and fruit
are excellent sources of cancer-preventive component and have gained a lot of interest for
their potential in cancer chemoprevention and therapy (Table 2.1). More than 35
plant-based foods that exert cancer-preventive effects have been identified, including
soybeans, ginger, garlic, onion, turmeric, tomatoes and cruciferous vegetables. The
structurally and functionally diverse bioactive compounds within these foods include
numerous agents such as carotenoids, vitamins, dietary fiber, probiotics, prebiotics, fatty
acids and phenolics(35). Numerous cell-cultured and animal model studies have been
conducted to evaluate their preventive ability to cancer. Growing evidence has
demonstrated that these bioactive component have the ability to prevent the progression
of cancer through multiple mechanisms, for example, by modulation of miRNAs, cellular
signaling, and epigenome(36).
Generally, natural products and phytochemicals can serve both as chemopreventive
as well as chemotherapeutic agents. However, chemopreventive agents can be delivered
in foods or as dietary supplements with little or no toxicity. In recent yeas, the effects of
phytochemicals on cell transformation and suppression of transformed cells during the
carcinogenesis have been a hot topic. Thus, it has been clear that exposure to
phytochemicals, both via diet or at pharmacological doses, yields alteration in key
genomic responses, which may stop or delay the process of carcinogenesis(37). Herein,
we took isoflavones and Epigallocaechin-3-gallate as examples of chemoprevention
agents.
Isoflavones are a group of phytochemicals that have been shown to have remarkable
efficacy in cancer prevention and therapy, especially three major constituents, genistein,
diadzein and glycitin(38). Isoflavones, in particular, genistein, have been extensively
studies as antitumor agent. It is believed to influence the differentiation process of
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mammary tissue and inhibit proliferation of various cancers by decreasing EGF mRNA
coupled with inhibition of tyrosine kinase, and altering the expression of NF-κB, which
profoundly decrease tumor growth as cell signaling pathways are crucial to tumor
maintenance(39).
Epigallocaechin-3-gallate (EGCG) has been extensively studied for their
chemopreventive and chemotherapeutic properties. EGCG has been shown to exert
numerous anticancer effects, including antiangiogenic activity by influencing the
transcriptional expression of vascular endothelia growth factor (VEGF)(40), inhibiting
phosphorylation of Her-2 receptor in breast cancer cells(41), inducing apoptosis in
estrogen receptor-(ER-) independent breast cancer cells(42), inhibiting rumor initiation
and promotion by inhibiting signal transduction pathways via NF-κB(43), inhibiting
proteasome formation(44), inhibiting glucose-regulated protein activity(45), inhibiting
insulin-like growth factor (IGF-IR)(46), and preventing invasion of tumors by inducing
HMG-box transcription factor 1 (HBP1) transcriptional repressor The HBP1 transcriptional repressor participates in RAS-induced premature senescence(47).
Sulforaphane is an isothiocyanates that mainly found in cruciferous plans, such as
broccoli and cabbages. The anti-inflammatory and anti-cancer effects of sulforaphane
have been extensively studied. It has been documented to inhibit the phosphorylation of
Akt, JNK and ERK proteins, which will inhibit their activities. Suforaphane is able to
inhibit the gene expression of iNOS and COX-2, which are two pro-inflammatory
proteins. Furthermore, it has been shown to modulate Nrf2 pathway and induce the gene
expression of a serial of phase II detoxification and antioxidant enzymes including HO-1
and NQO1. These findings have suggested that the anti-inflammatory effect of
sulforaphane may contribute to its anti-carcinogenic effects.
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Table 2.1 Classification and sources of dietary phytochemicals possessing antitumor
activites (Adapted from González-Vallinas et al., 2013)(3)
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2.2.3 Mechanisms and molecular targets critical to chemoprevention
Carcinogenesis is considered to be a multistep process in which distinct molecular
and cellular alterations occur. Tumor development consist several separate, but closely
linked stages- tumor initiation, promotion and progression. Various molecular key
signaling pathways become uncontrollable and ultimately lead to their malfunctions
during these stages.
Initiation is a rapid and irreversible process that involves multiple extracellular and
intracellular events. These include the uptake of or exposure to a carcinogen, its
distribution and transport to organs and tissues where metabolic activation and
detoxification occurs, and the related interaction of reactive species with target-cell DNA,
leading to genotoxic damage. During this initial step, biotransformation enzymes (phase I
enzymes, including the cytochrome P450 system) convert the pro-carcinogens to the
active carcinogens. Phase II enzymes (e.g., glucoronidases, sulfotransferases) play a role
in the detoxification of activated carcinogens. Reactive oxygen species (ROS) are
normally generated by normal oxidative metabolism or may result as part of the
breakdown of xenobiotic compounds. Extensive DNA damage resulting form ROS is
associated with increasing gthe rate of mutation within cells and thereby promoting
oncogenic transformation. Some chemopreventive compounds have been classified as
anti-iniator, including genistein, aspirin, selenium, indoles, resveratrol, and allyl sulfur
compounds(48).
Tumor promotion is believed to be relatively lengthy and reversible process in
which actively proliferating preneoplastic cells accumulate. It is characterized by
deregulation of signaling pathways that normally control cell proliferation and apoptosis.
Genes that control cell cycle are often mutated in human cancers. p27 mutations are
found in most pancreatic tumors. Similarly, the majority of colon cancers exhibit p53
mutation. Mutations in these genes that regulate cell cycle progression lead to the
uncontrolled proliferation of the transformed cells. Moreover, a dysfunctional cell-death
system is often prominent during the promotion stage. Pathways that are involved in cell
death and renewal are greatly altered. Chemopreventive agents can targets include, but
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are not limited to, hormone receptors, cell cycle check-point proteins, transcription
factors,

mitogen-activated

protein

kinases,

rate-limiting

enzymes

including

ornithinedecarboxylase, cyclooxygenase, cell junctions, and tumor suppressor gene(37).
Progression is the final stage of neoplastic transformation. In this stage, the tumor
will form with invasive and metastatic potential(5). Dietary bioactive components have
been documented to be able to intervene one or more of the abnormal molecular
pathways highly related to carcinogenesis including carcinogen metabolism, DNA repair,
cell growth, cellular apoptosis, cell cycle progression, angiogenesis, and metastasis(37).
Chemopreventive agents are divided into two main categories: blocking agents and
suppressing agents(49). As blocking agents, bioactive compounds from fruit or
vegetables are able to prevent carcinogens from reaching the target sites, from
undergoing metabolic activation or from subsequently interacting with crucial cellular
macromolecules, such like DNA, RNA and proteins. In contrast, suppressing agents
inhibit the malignant transformation of initiated cells, in either the promotion or the
progression stage. Chemopreventive agents can block or reverse the premalignant stage
(initiation and promotion) of multistep carcinogenesis. They can also at least retard the
development and progression of precancerous cells into malignant ones(5).
2.3 Polymethoxyflavones

2.3.1 Introduction to polymethoxyflavones
The Citrus species fruits are important crop because of their industrial value,
especially in foods and cosmetics. Current annual worldwide citrus production is
estimated at over 105 million tones, with more than half of this being orange. Large
amounts of by-products, which are composed of peel and seeds, are produced every year
in citrus processing plants and these may contain high levels of potentially bioactive
compounds. In some regions of the world, citrus peel has been regarded as a traditional
medicine for relieving stomach upset, cough, skin inflammation, muscle pain, and
ringworm infections, and hypertension(7). Phytochemical investigations into Citrus
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species have shown that the peel contains flavonoids, limonoids and coumarins(50).
As a large group of plant secondary metabolites derived from the phenylpropanoid
pathway, flavonoids are a widely distributed group of bioactive compounds and some of
them, such as hesperidin, naringin and polymethoxyflavones (PMFs), are characteristic of
citrus plans(51). PMFs is a unique group of compounds that bearing two or more
methoxy groups on their basic benzo-ϒ-pyrone (15-carbon, C6-C3-C6) skeleton with a
carbonyl group at the C4 position (Figure 2.1). PMFs are one of the major constituents
and exist almost exclusively in citrus plant peel. More than 20 different PMFs have been
isolated and identified from citrus fruit, such as sinensetin (5,6,7,3 ′ ,4 ′
-pentamethoxy-flavone), nobiletin (5,6,7,8,3 ′ ,4 ′ -hexamethoxyflavone, NBT),
tangeretin (5,6,7,8,4 ′ - pentamethoxyflavone, TAN), and 3,5,6,7,8,3 ′ ,4 ′
-heptamethoxyflavone(52). PMFs gained especial interest to disease chemoprevention
because they showed a broad spectrum of biological and pharmacological properties.
Besides, several hydroxylated PMFs (Figure 2.2), in which one or two methoxy groups
are replaced by hydroxyls in different positions, have also received considerable attention
in recent years, due to their more potent activity than their parent PMFs in the prevention
and treatment of several diseases(7)(52).
Figure 2.1 Chemical structure of PMFs. (Adapt from Lai et al.)(53)
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Figure 2.2 Chemical structures of hydroxylated PMFs (Adapt from Lai et al.)(53)

2.3.2 Biological activities of PMFs

2.3.2.1 Anti-inflammatory activities of PMFs
Chronic inflammation has been shown to associate with numerous human diseases,
including cardiovascular diseases, neurological disorders, obesity, metabolic syndromes,
rheumatoid arthritis, inflammatory bowel disease, and several types of cancer.
Anti-inflammatory activity is considered to be the one of the most significant biological
properties of PMFs. Research evidence have demonstrated that citrus flavonoids,
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especially PMFs, are directly associated with the inhibition of enzymes involved in the
inflammation, such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2)
and NADPH oxidase that generate inflammatory mediators like NO, prostaglandin E2
(PGE2) and superoxide anion(10,54).
Nobiletin (NBT), which is a potential anti-inflammatory agent within the PMFs, has
recently been demonstrated to inhibit matrix degradation of the articular cartilage and
pannus formation in osteoarthritis and rheumatoid arthritis by inhibiting the expression of
promatrix metalloproteinase-9 (MMP-9) and prostaglandin E2 (PGE2) in human synovial
fibroblasts by selectively downregulating COX-2 activity(55)(56). Cell culture studies
have showed that NBT was able to inhibited LPS-induced production of NO and PGE2 in
RAW 264.7 macrophages(57), and suppressed gene expression of pro-inflammatory
cytokines. Animal model studies demonstrated that NBT inhibited TPA-induced skin
inflammation(10)

and

suppressed

dextran

sulfate

sodium-induced

colitis(12).

5-Demethylnobiletin isolated from Sideritis tragoriganum exerts anti-inflammatory
activity in 12-O-tetradecanoylphorbol 13- acetate (TPA)-induced ear edema and acute
mouse paw edema induced by carrageenan and phospholipase A2 (PLA2). The inhibitory
effect of 5-demethylnobiletin contributes to inflammatory cell infiltration, inhibition of
leukotriene B4 formation and direct inhibition of 5-lipoxygenase (5-LOX)(58).
The anti-inflammatory effects of tangeretin and 5- demethyltangeretin were
investigated

in

a

DMBA/TPA-induced

skin

carcinogenesis

model(59).

5-Demethyltangeretin was found to be more potent than tangeretin at reducing tumor
incidence, number, and size because it displayed a stronger inhibitory effect on iNOS and
COX-2 expression. Stronger inhibition of PI3K/Akt signaling was also found by
5-demethyltangeretin.

Molecular

docking

analysis

showed

the

structure

of

5-demethyltangeretin to have more hydrogen bonding interac- tions with residues of
PI3K, COX-2, and AKT, which may account for the superiority of its anti-inflammatory
effects rel- ative to tangeretin.
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2.3.2.2 Anti-carcinogenic activities of PMFs
There are numerous evidences suggested a strong correlation between inflammation
and cancer initiation and proliferation. The proposed mechanisms were concluded as:
direct interaction of viral DNA into the host genome, immunosuppression caused by viral
infection leading to failure to inhibit malignancy, and production of ROS and RNS which
cause damage to the host DNA(60).
PMFs were documented to show protective effects against multiple types of cancer
in vitro and in vivo study. PMFs inhibit carcinogenesis by induction of cell cycle areest
and cellular apoptosis, inhibition of cell proliferation, cancer cell mobility, angiogenesis
and metastasis processes(7). Moreover, PMFs have also been shown to reduce the
invasion of tumors in animal models, to induce the differentiation of myeloid leukemic
cells, and to suppress proliferation of cancer cells. Nobiletin and tangeretin are two most
abundant PMFs in citrus peels. Comparative studies were conduced to investigate the
growth inhibitory effects between PMFs including nobiletin, tangeretin, and
polyhydroxyflavonoids on HTB43 human squamous-cell carcinoma. NBT and TAN were
showed to significantly inhibit HTB43 cells growth, however, the hydroxyflavonoids did
not show any significant inhibition(61). NBT also has been found to show various
protective effects against multiple cancers in vivo. Specifically, dietary NBT significantly
suppressed colon carcinogenesis in several colon cancer animal models(62)(12)(13).
NBT at 0.01% or 0.05% significantly decreased the incidence of colon tumors, PCNA
positive index, and levels of PGE2. Moreover, NBT increased the apoptosis in
AOM-induced colonic adenocarcinoma in F344 rats. In another study 0.01% of NBT
decreased the incidence and multiplicity of colonic tumors and serum leptin in
AOM/DSS-induced colon carcinogenesis in ICR mice. Furhtermore, NBT showed
anti-invasion activity by inhibited matrix metalloproteinase (MMP) activity in the rat(63).
Tangeretin exert inhibition the initiation of cancer by modulating hepatic enzymes and
affecting xenobiotic activation and detoxification in the liver. Tangeretin was documented
to inhibit cancer cell growth and metastasis by inhibiting cell invasion and adhesion(64).
Lust et al. claimed that TAN exerted its anticancer effect in erythroleukemia K562 by
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activating the unfolded protein response.
Recent studies suggested that hydroxylated PMFs exhibited much potent anticancer
activities than those produced by their permethoxylated counterparts. 5Demethylnobiletin
and 5Demethyltangeretin were found to induce both cell cycle arrest and apoptosis in
human lung cancer cells, however their permethoxylated counterparts, nobiletin and
tangeretin, did not cause any significant effects(9). Qiu et al. also observed superior
anticancer activities produced by 5DN, 5DH, and 5DT than their permethoxylated
counterpart, nobiletin, HMF, and tangeretin, respectively(16). Furthermore, another two
recent studies also proved that 3´-hydroxy-5,6,7,4´-tetramethoxyflavone and 5DH
showed stronger inhibitory effects on the growth of human breast (41)and leukemia cells
(68) than those exhibited by their permethoxylated counterparts, 5,6,7,3´,4´pentamethoxyflavones and HMF respectively.

Furthermore, studies also documented

that 3´-hydroxy-5,6,7,4´-tetramethoxyflavone and 5DH showed stronger inhibition on the
growth of human breast(65) and leukemia cells(66) than those exhibited by their
permethoxylated counterparts, 5,6,7,3´,4´- pentamethoxyflavones and HMF, respectively.
2.3.2.2 Anti-atherosclerosis activities of PMFs
Citrus flavonoids have been shown to lower total cholesterol concentration in blood
of hamster by reducing the hepatic production of cholesterol containing lipoproteins, and
thus reduce the risk of cardiovascular disease(67). Li et al. reported that PMF food
supplement may ameliorate hypertriacylglyceridemia and its anti-diabetic effects in
hamsters by adipocytokine regulation and peroxisome proliferatiors activated receptor-α
(PPARα) and PPARγ activation.(68) TAN has been reported to decrease total cholesterol
in plasma, modulate apoB-containing lipoprotein metabolism, and reduce the levels of
triacylglycerol, very low-density lipoproteins and low-density lipoproteins in HepG2
cells(69). A recent study showed that NBT is able to reduce the circulating concentrations
of VLDLs and LDLs in the blood, and also inhibit macrophage-derived foam-cell
formation at the site of lesion development within a vessel wall(70). NBT is also reported
to enhance both differentiation and lipolysis of adipocyte by activating signaling cascades
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mediated by cAMP/CREB(71).
2.3.3 Biotransformation of polymethoxyflavones
Growing evidence has demonstrated that biotransformation can greatly determine
the biological activity of dietary bioactive compounds(23). Because the metabolites
generated by biotransformation may have stronger activities in comparison with their
parent compound(72). PMFs have been widely reported to have broad spectrum of
biological properties, however, the information about their biotransformation is largely
unclear. In this section, the biotransformation of major PMFs will be disscussted.
2.3.3.1 Nobiletin
Nobiletin has been shown to undergo extensive biotransformation after digestion.
Several metabolites of NBT were generated with different chemical structures. Murakami
et al. firstly investigate the absorption and metabolism of NBT using rat liver S9 mixture.
The results showed that co-incubation of NBT and S9 mixture for 24 hours resulted in the
formation of 3’-demethylnobiletin as a metabolite of NBT(73). Koga et al. reported the in
vitro metabolism of nobiletin using liver microsomes of rats, hamsters and guinea pigs
and ten cDNA-expressed rat cytochrome P450. Nobiletin was transformed to five
metabolites after aerobical incubation with NADPH and animal liver microsomes (Figure
2.3). The LC-MS and 1H-NMR data confirmed that these were 4’hydroxy(OH)-, 7-OH-,
6-OH-, 3’,4’-diOH- and 6,7-diOH-metabolites, respectively(74). In vivo studies, Yasuda
et

al.

found

that

the

main

urinary

metabolites

of

NBT

was

4’-hydroxy-3’,5,6,7,8-pentamethoxyflavone after orally administered to rat, by using
three-dimensional HPLC equipped with a photodiode array detector(75). In a mice model,
Li et al. showed that the major nobiletin metabolite of mouse urine is identified as
4’-demethylnobiletin with the concentration of 28.9 µg/mL in urine, whereas
3’-demethylnobiletin is a minor metabolite(76). In another mouse study, Zheng et al.
identified three major metabolites of NBT in urine, namely 5,3’-didemethylnobiletin,
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5,4’-didemethylnobiletin, and 5,3’,4’-tridemethylnobiletin

by comparing their ESI-MS

and HPLC profiles with those of authentic standards synthesized by a multistep
route(77).
Figure 2.3 Postulated metabolic pathways of NBT in animal liver (Adapted form Koga
et.al) (74)

In our recent study, we identified and quantified major metabolites of NBT in the
colonic mucosa of NBT-fed mice, which are 3'-demethylnobiletin, 4'-demethylnobiletin,
and 3', 4'- didemethylnobiletin. Importantly, the levels of these metabolites were about
20-fold higher than NBT itself. It is likely that their formation is undergo phase I and II
metabolism as well as biotransformation by gut microbiome (Figure 2.4). In conclusion,
these results suggested that the metabolites of NBT might greatly contribute to the
biological properties elicited by dietary NBT.
2.3.3.2 5-Demethylnobiletin
5-Demethylnobiletin was demonstrated to exhibited superior inhibitory effects
against multiple types of cancers, when compared to its counterparts, nobiletin(16,78).
In our recent study, three major metabolites of 5-DN in the urine from mice fed with
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5-DN were identified as 5,3’-didemethylnobiletin, 5,4’-didemethylnobiletin, and
5,3’,4’-tridemethylnobiletin, respectively by LC-ESI-MS and HPLC method (Figure 2.4).
Among these metabolites, 5,4’-didemethylnobiletin was the most abundant one in urine
samples. In addition, significant amount of 5DN and its metabolites were conjugated as
glucuronides and/or sulfates forms by phase II metabolism(77).
2.3.3.3 Tangeretin
Breinholt et al. identified two major metabolites of tangeretin after incubation with
human

microsomes,

namely

4’-hydroxy-5,6,7,8-teramethoxyflaone

and

5.6-dihydroxy-4’7,8,-trimethoxyflavone. By comparison with UV spectra and LC/MS
fragmentation patterns of standards, three minor metabolites of Tan were also found to be
demethylated at the 4’,7-,4’,6-positions or hydroxylated at the 3’-and demethylated at the
4’-positions, respectively (Figure 2.5)(79).
Figure 2.4 Proposed metabolic pathway of tangeretin and involvement of specific CYP
isozymes. (Adapted from Breinholt et al.)(79)

In an animal study conducted by Nielsen et al., the in vivo biotransformation of
flavone was investigated by analyzing urine and feces samples from rats after repeated
administration of 100 mg/kg body weight/day tangeretin. The results indicated that the
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major

metabolites

of

TAN

4’-hydroxy-5,6,7,8-tertramethoxyflavone,

in

urine

and

feces

were

3’,4’-dihydroxy-5,6,7,8-tetramehoxyflavone,

and 4’6’-dihydroxy-5,7,8-trimethoxyflavone, respectively. Six other minor metabolites
were also found in these samples. The authors also concluded that the metabolites
identified were either hydroxylated or demethylated derivatives of the parent compound
and metabolic changes were found primarily to occur in the 4’ postion of the B-ring in
TAN(80).
2.4 Combination treatment for cancer chemoprevention

2.4.1 Introduction to combination treatment
Combination treatments with two or more agents at lower doses that targeting
different molecular targets might produce enhanced biological activities than those
produced by each individual agent at higher doses. The concept that using a combination
of agents for cancer chemoprevention has recently received much attention. A growing
body of evidence has suggested that the combination of cancer chemopreventive agents
with distinct mechanisms of action may produce synergistic effects on efficacy and
minimize possible toxicity associated with high dose administration(19).
Numerous studies have demonstrated the benefits of combining multiple
pharmaceutical drugs and combining dietary bioactive components with pharmaceutical
drugs against cancer. For example, Schwartz et al. showed that the combination of drug
sulindac and oliver oil produced significantly stronger inhibition on the aberrant crypt
foci (ACF) than those produced by each agent alone. This combination treatment was
also found to effectively down-regulate colonic mucosa BCL-2 expression and COX-2
expression(81). Constantinou et al. demonstrated that the tamoxifen/daidzein (soy
isoflavone) combination synergistically reduced mammary tumor (induced by 7,12
dimethylbenzanthracene in rat) multiplicity, incidence, and tumor burden by 76%, 35%,
and 95%, respectively, and increased tumor latency by 62% when compared to the
positive controls(82). Bose et al. reported that treatment with fish oil and
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(-)-epigallocatechin-3-gallate significantly reduced the tumor incidence, tumor number,
levels of PGE2, nuclear β-catenin and phosphorylated Akt in ApcMin/+ mouse model(83).
Recently, statins have been suggested to be a candidate in combination with dietary
bioactive compounds for cancer chemprevention and treatment.
2.4.2 Introduction to statins
Statins

are

a

family

of

small

molecule

inhibitors

of

3-hydroxy-3methyglutarylcoenzyme-A (HMG-CoA) reductase that either derived from
fungal fermentation or chemically synthesized. The statins family consists of several
drugs: lovastatin (Mevacor®), simvastatin (Zocor®), mevastatin (Compactin®), fluvastatin
(Lescol®), pravastatin (Pravachol®), atorvastatin (Lipitor®) and rosuvastatin (Crestor®)
(Figure 2.6). Statins have been extensively prescribed to reduce cholesterol levels and has
mostly recognized for ameliorating cardiovascular outcomes in both general po;ulation
and in cardiovascular disease patients(84).
Figure 2.5 Chemical structures of HMG-CoA reductase inhibitors (Statins) (Adapted
from shitara et al., 2006)(85)
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Numerous experimental and clinical evaluations revealed that statins have
pleiotropic properties that can potentially benefit human health by preventing a number
of chronic diseases such as cancer. In vitro studies have documented the anticancer
effects of statins against multiple cancer cells including lung(86,87), colon(88,89),
leukemia(90,91), breast(92), pancreatic(93), and prostate cancer(94). The molecular
mechanisms of anticancer activities of statins could be concluded from these studies.
Statins reduced level of mevalonate, which sits at the apex of cholesterol synthesis
pathway, and its downstream products, by inhibiting HMG-CoA reductase. The lipid
isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate are critical
in post-translational modification of membrane related proteins, like Ras and Rho small
GTP-binding proteins. Thus, by inhibiting the biosynthesis of mevolonate and
downstream lipid isoprenoids, statins can greatly regulate the multiple molecular
pathways that related to carcinogenesis including membrane integrity, cell adhesion, cell
motility, cell cycle progression, cell survival, cell transformation, angiogenesis,
endocytosis, oxidative stress, and the cellular response to genotoxic stress(95–97).
2.4.3 Potential enhancement effect by using statins in combination with bioactive
component against cancer
The presence of dietary bioactive compounds in fruits and vegetable can help to
decrease the risk of multiple types of cancer. Recently, accumulating studies have
suggested that the combination of statins with dietary agents can exert enhanced
anti-cancer effects both in vivo and in vitro against various cancers. As for in vitro studies,
Ledezma et al. reported that atorvastatin or pravastatin caused cytotoxity in murine
melanoma B116F10 cells, when combined with ajoene from garlic. And the inhibitory
effect produced by the combination treatment was more potent than those produced by
each single agent(98). Wali et al. demonstrated that the combination of statins (mevastatin,
simvastatin, lovastatin, and pravastatin) and ϒ-tocotrienol produced synergistic effects on
inhibiting proliferation of malignant mouse +SA mammary adenocarcinoma cells. The
combination treatment accumulated cell population in G0/G1 phase, increased the
expression of p27, and decreased the expression of cylcin D1, CDK2, and

22

hyperphosphorylation of Rb protein(99,100). Xiao et al. showed that combined treatment
of atorvastatin and celecoxib (a COX-2 selective nonsteroidal anti-inflammatory drug)
synergistically inhibited HCT116 and HT29 human colon cancer cell growth. And this
synergy was associated with increased levels of p21, p27, and phopho-JNK; decreased
levels of phosphor-AKT and hyper-phosphorylated Rb; and activation of caspase cascade.
Atorvastatin/celecoxib combination also selectively modified membrane localization of
smll G-proteins, such as RhoA, RhoB and RhoC, which may contribute to the synergistic
effect. Lu et al. reported the synergistic inhibitory effects of atorvastatin and green tea
polyphenol combination on human lung cancer cells. This combination of each agent at
low dose significantly increased apoptosis by modulating the expression of key signaling
proteins related to apoptosis, such like the decreased levels of Mcl-1, which was an
anti-apoptotic protein that usually overexpressed in lung cancer. The combination
treatment also decreased levels of cyclin D1 and CDK-6, which were key proteins in cell
cycle regulation. The in vivo study conducted by the same group demonstrated that the
polyphenol E/atorvastatin combined treatment synergistically decreased NNK-induced
lung tumor multiplicity and tumor size by 56% and 55%, respectively in female A/J mice.
However, single treatment of polyphenol E or atorvastatin alone did not produce
significant effect on tumorigenesis(20).
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CHAPTER 3
DIETARY 5-DEMETHYLNOBILETIN INHIBITS CIGARETTE CARCINOGEN
NNK-INDUCED LUNG TUMORIGENESIS IN MICE
3.1 Introduction
Lung cancer, a major public health problem, is the leading cause of cancer mortality
in both men and women in the United States(101). However, human trials on the
prevention and treatment of lung cancer have not produced satisfactorily promising
results. The 5-year survival rate for lung cancer patients (18.1%) is significantly lower
than many other leading cancer sites, including the colon and rectum (65.1%), breast
(89.8%) and prostate (98.7%)(26). Therefore, there is an urgent need of effective
strategies for the prevention of lung cancer. Nearly 90% of all lung cancers are directly
linked to cigarette smoking(102). Among more than 60 carcinogens in cigarette
smoke(28), 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK) is considered to be the
most potent etiological factor in the initiation and progression of lung carcinogenesis in
human(103–105). Lung tumors induced by NNK in the female A/J mice share many
histopathologic and molecular characteristics with human lung carcinogenesis, and
therefore provides an excellent model for lung cancer chemoprevention study(106).
Polymethoxyflavones (PMFs) are a unique class of flavonoids specifically found in
the citrus fruits such as sweet oranges (Citrus sinensis) and mandarin oranges (Citrus
reticulate)(15).Studies have shown that PMFs exhibit a series of biological activities
including anti-carcinogenic, anti-inflammatory, and antiviral effects(7,107–109). Among
more than 20 different citrus PMFs identified, 5-demethylated PMFs are a unique
subclass that has been associated with many beneficial biological activities For example,
potent inhibitory effects of 5-demethylated PMFs have been demonstrated by us and
others

on

multiple

types

of

human

cancer

cells(9,16,65,78,110–113).

5-Demethylnobiletin (5DN) is one of the most abundant 5-demethylated PMFs from
citrus fruit. Studies have showed strong inhibitory effects of 5DN on human lung cancer
in both in vitro cell culture models and an in vivo xenograft model(9,78,114). However,
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no information is available on the effects of 5DN on cigarette carcinogen-induced lung
tumorigenesis.
Biotransformation of dietary bioactive components is crucial for their in vivo
biological effects. Studies have showed that the metabolites of flavonoids may have
significant bioactivities after oral administration(115,116). In the previous study, we
identified three major metabolites of 5DN in the urine of 5DN-fed mice (Fig. 3.1), i.e.
5,3ʹ-didemethylnobiletin

(M1),

5,4ʹ-didemethylnobiletin

(M2)

and

5,3ʹ,4ʹ-tridemethylnobiletin (M3)(77). Interestingly, these metabolites were found to be
more potent in inhibiting the growth of human colon cancer cells in culture(77). In this
study, for the first time, we investigated the inhibitory effects of 5DN on the
NNK-induced lung tumorigenesis in female A/J mice. Furthermore, we identified the
major metabolites of 5DN in the lung tissue of 5DN-fed mice, and examined their effects
on the growth of both human and mouse lung cancer cells.

Figure 3.1 Chemical structures of 5-Demethylnobiletin and its three metabolites

25

3.2 Materials and Methods
3.2.1 Animals，diets, and experimental design
The protocol of this animal study was approved by Institutional Animal Care and
Use Committee of University of Massachusetts Amherst (#2014-0079). Five-week-old
female A/J mice (18-22g) were obtained from The Jackson Laboratory (Bar Harbor, ME)
and housed in plastic cages (5 mice/cage) with free access to water and a basal diet, under
controlled conditions of 22±2 °C and 50±10% humidity in a 12-h light-dark cycle. The
mice were randomly divided into four groups as detailed in fig. 3.2, and maintained on
AIN-76A diet (Dyets, INC., Bethlehem, PA), ad libitum, for 1 week. Studies have
showed that AIN-76A diet provide more numerous and reproducible lung tumors in
response to NNK than other commercial rodent diets in A/J mouse strain(117,118). After
1-week acclimation, the mice in positive control group and in 5DN treatment group
received an i.p. injection of saline containing NNK (100mg/kg body weight). Mice in
negative control received an equal volume of saline (vehicle control). Two days after
NNK injection, the mice in treatment groups were fed with the AIN-76A diets
supplemented with 5DN (0.025% or 0.05% w/w), and the mice in vehicle control group
and NNK positive control group were maintained on the standard diet. Sixteen weeks
after NNK injection, all mice were sacrificed. Liver and spleen were harvested and
weighted. Intact lungs were excised and analyzed for tumor number and size under
dissection microscope. A part of the lungs without tumors were carefully dissected and
rapidly frozen for metabolites analysis, and the rest of lungs were infused with 10%
neutral buffered formalin for 48 hours, then transferred to 80% alcohol. The results were
present as the percent of mice with lung tumors (incidence), the mean number of tumors
per mouse ± SEM (multiplicity) and the mean volume of tumors ± SEM (calculated
according the formula: V=4/3πr3; r=radius, the average of the longest and shortest
diameters).

26

Figure 3.2 Experimental design to determine the inhibitory effect of 5DN on
NNK-induced lung tumorigenesis in the A/J mouse model. Six-week-old mice were
injected intraperitoneally with NNK (100mg/kg body weight) or saline after 1-week
acclimation. 2 days after NNK injection, mice were fed with standard diet (AIN-76A) or
standard diet containing 0.025% or 0.05% (w/w) 5DN till the end of the study. After 16
weeks on experimental diets, all mice were sacrificed and lungs were harvested for
evaluation of tumor development. Detailed information was provided in Materials and
methods.
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3.2.2 Tumor Histology and Immunohistochemical analysis
The fixed lung tissue were embedded in paraffin, sectioned (5µm) and stained with
hematoxylin and eosin (H&E) for histopathological analysis. Lung proliferative lesions
were diagnosed as alveolar cell hyperplasia and adenoma according to established
criteria(119). The lung tumors were not sub-classified into adenoma and adenocarcinoma
because it was impractical to evaluate malignancy at 16 weeks after NNK injection
(120,121). Immunohistochemical analysis was performed in the lung tissue sections
(20,122,123). Cell proliferation in the lung tissue was determined by positive staining of
proliferating cell nuclear antigen (PCNA) and p21.
3.2.3 Quantification of 5DN and its metabolites in lung tissues
Lung tissues were homogenized in methanol (50% in phosphate buffered saline,
pH=5.00) and then extracted with ethyl acetate for three times. Pooled ethyl acetate
fractions were dried under vacuum and reconstituted in 50% methanol. Identification and
quantification of 5DN and its metabolites were performed using HPLC method as we
previously described(77,124). 5DN, M1, M2, and M3, with purity greater than 98%, were
used as external standards and tangeretin (>98%) was used as an internal standard.
3.2.4 Analysis of cell viability, cell cycle and apoptosis
Assays for cell viability, cell cycle and apoptosis were conducted as we previously
described(9,19,110). A549 human lung cancer cells were purchased from American Type
Cell Collection (ATCC, Manassas, VA, USA). CL13 mouse lung cancer cells were
derived from NNK-induced lung tumors, and were from Dr. Steven A. Belinsky
(Lovelace Respiratory Research Institute, Albuquerque, NM). Both cell lines were
cultured in RPMI 1640 media. In brief, cancer cells were seeded in 96-well plates. After
24 h, cells were treated with 5DN or its metabolites, and the cell viability was quantified
by MTT method. Cells were seeded in 6-well plates for cell cycle and apoptosis analysis.
After 24 h of incubation for cell attachment, cells were treated with 5DN or its
metabolites. Floating cells and adherent cells were combined to be subject to cell cycle
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and apoptosis analysis by flow cytometry as we described previously(9,78,110). DMSO
was used as vehicle to deliver 5DN and its metabolites to the cells. The final
concentration of DMSO in all experiments was 0.1% v/v in cell culture media.
3.2.5 Immunoblotting
Whole cell lysate were prepared following the procedure we described
previously(9,78,110). Briefly, cells were seeded in 150mm cell culture dishes then treated
with 5DN and its metabolites after 24 hours incubation. After another 24 or 48 hours,
cells were collected with cell scrapers and subject to Western blotting analysis.
3.2.6 Statistical analysis
Data were presented as mean ± SEM or mean ± SD. Student’s t-test was used to test the
mean difference between two groups, whereas analysis of variance (ANOVA) followd by
Tukey HSD test was used for the comparison of differences among three or more groups.
Tumor incidence was analyzed by Fisher’s exact probability test. Differences were
considered statistically significant when p<0.05.
3.3 Results and Discussion
3.3.1 Dietary 5DN did not exhibit toxicity in mice
To establish the chemopreventive effects of 5DN, NNK-treated female A/J mice
were subjected to dietary treatment of 5DN (0.025% and 0.05% w/w in diet) for 16
weeks. These two doses were equivalent to 125 mg and 250 mg of 5DN per day in human
approximately, which is conveniently achievable through dietary supplementation. All
mice survived the entire experimental period. During the treatment period, no significant
difference was observed in the appearance or behavior of the mice between 5DN-treated
groups and control groups. The body and selected tissue weights of the mice in all groups
at the termination of the study were shown in Table 3.1. There was no significant
difference in body weight, spleen weight or spleen relative weight (%RW) among all
groups, suggesting that there is no apparent toxicity by dietary 5DN treatment. However,
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the liver weight of the mice from the positive control group was significantly lower than
that of other groups. Similar results were observed by Kim et al(120) and Li et al(125),
suggesting that NNK injection had caused a decrease in liver weight, and 5DN treatment
ameliorated this effect. Overall, dietary administration of 5DN did not exhibit noticeable
toxicity in female A/J mice.
Table 3.1 Final body, liver, relative liver, spleen and relative spleen weights
Group

Mice

Body

No.

weight (g)

Liver

Spleen

W (g)

% RW

W (g)

% RW

Negative control

10

23.8±3.0

1.04±0.22a

4.38±0.56a

0.078±0.018

0.32±0.08

Positive control

20

23.5±2.0

0.92±0.11b

3.91±0.45b

0.070±0.018

0.30±0.08

0.025% of 5DN

20

24.3±2.9

1.02±0.16a

4.21±0.65a

0.078±0.015

0.31±0.09

0.05% of 5DN

20

23.5±2.8

1.04±0.12a

4.43±0.36a

0.075±0.013

0.32±0.06

All values represented mean ± SEM, and different notation (a or b) indicated statistically
significant difference (P<0.05) according ANOVA analysis.

3.3.2 Dietary 5DN inhibited tumorigenesis in NNK-treated mice
After NNK or vehicle control injection, mice were maintained for 16 weeks. Our
results (Tab. 3.2) showed that lung tumors had developed in 100% of the mice in the
positive control group, whereas no lung tumor was found in the negative control mice.
All lung tumors were identified as solid adenomas based on the histological analysis,
which was consistent with previous reports(20,120,126). Dietary 5DN treatments at 0.025%
or 0.05% did not reduce the tumor incidence. However, 0.05% of 5DN significantly
decreased the tumor multiplicity from 14.91±1.04 to 11.72±0.94 in comparison to the
positive control group. Moreover, dietary administration of 5DN showed a
dose-dependent inhibition of tumor volume, i.e. 0.025% and 0.05% of 5DN decreased the
tumor volume by 33.6% (from 0.4220 ± 0.0255 to 0.2800 ± 0.0132) and 52.4% (from
0.4220 ± 0.0255 to 0.2800 ± 0.0132), respectively. Representative images of lung tumors
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from positive control group and 0.05% of 5DN treatment group have been shown in Fig
3.3. H&E stainings showed that the solid adenomas in the positive control group (Fig
3.3A) arranged into clusters and had varying degrees of differentiation, and normal
alveolar architecture was lost. In contrast, we observed that the lungs from 0.05% of 5DN
treatment group (Fig 3.3A) had a moderate decrease in the development of solid adenoma,
and were without significantly losing the alveolar architecture.
Table 3.2 Effects of dietary 5DN treatment on NNK-induced lung tumorigenesis in mice
Tumor

Tumor

Tumor

incidence (%)

multiplicity

Volume (mm3)

10

0 (0/10)

0

0

Positive control

20

100 (20/20)

14.91±1.04a

0.422±0.026a

0.025% of 5DN

20

100 (20/20)

14.73±0.93a

0.280±0.013b

0.05% of 5DN

20

100 (20/20)

11.72±0.94b

0.201±0.010b

Group

Mice No.

Negative control

Tumor multiplicity and volume were presented as mean ± SEM, and different notation (a or b)
indicated statistically significant difference (P<0.05) according ANOVA analysis.

Uncontrolled cell proliferation is one of hallmarks of carcinogenesis. PCNA
expression is increased during cell duplication and plays a critical role in regulating DNA
replication, therefore it is often used as a key marker for cell proliferation(127). We
hereby determined the effects of 5DN on the expression level of PCNA in lung tissues
(Fig. 3.3B and D). Our results showed a high PCNA labeling index in lung tumors of the
mice in the positive control group, indicating a high cell proliferation rate (Figure 3.3B).
However, the PCNA labeling index was significantly lower in the lung tumors of the
mice treated with 5DN in comparison to that of positive control mice. Quantification of
PCNA staining showed a labeling index of 46 ± 3.2 in tumors of mice in positive control
group as compared with 23.6 ± 2.6 in mice treated with 5DN, reflecting a 48.7% decrease
in the proliferation index (Figure 3.3D). p21 is a key cyclin-dependent kinase inhibitor
involved in cell cycle progression and tumorigenesis(128). In humans, loss or decrease of
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expression of p21 correlated with poor prognosis of lung cancer(129). We examined the
effects of 5DN on p21 expression in NNK-induced lung tumors. As shown in figure 3.3C,
the expression of p21 can be detected in the lung tumors of positive control mice. The
expression level of p21 in the lung tumors of 5DN-treated mice was higher than that of
the positive control mice. Quantification of p21 staining showed dietary administration of
5DN significantly elevated the p21 protein expression level in lung tumors by 41.2% in
comparison to that of positive control mice. Increased p21 level may lead to lower cell
proliferation by inducing cell cycle arrest.
Figure 3.3 Effect of dietary 5DN on immunohistochemical staining of PCNA and p21 in
NNK-induced lung tumors. Representative lung sections from positive control and 5DN
treatment groups were shown. Data were presented as means ± SE and statistical
significance was analyzed by Student’s-t test.

(A) H&E stained lung sections from

positive control and 5DN treatment groups. (B) PCNA staining of lung sections from
positive control and 5DN treatment groups. (C) p21 staining of lung sections from
positive control and 5DN treatment groups. (D) Quantification of PCNA staining of lung
sections from positive control and 5DN treatment groups. The asterisks in the bar charts
indicated statistical significance in comparison with the control (p<0.05) by Student’s-t
test. (E): Quantification of p21 staining of lung sections from positive control and 5DN
treatment groups. The asterisks in the bar charts indicated statistical significance in
comparison with the control (p<0.05) by Student’s-t test.
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3.3.3 Quantification of 5DN and its metabolites in the lung tissues of 5DN-fed mice
The metabolism of bioactive dietary compounds, including flavonoids, is crucial for
their biological activities, because the metabolites produced from the parent compounds
after oral ingestion may have different biological activities than the parent compounds.
Therefore, metabolism may significantly alter the overall bioactivity of the parent
compounds. Our previous study has identified three major metabolites of 5DN in the
urine of 5DN-fed mice, namely M1, M2 and M3 (Fig. 3.1), and these metabolites,
especially M1 showed much stronger inhibitory effect on the grown of human colon
cancer cells(77). To better understand the chemopreventive effects of 5DN against lung
tumorigenesis, we determined the levels of 5DN and it metabolites in the lung tissue of
NNK-treated mice fed with 5DN, using HPLC method we established previously(77,124).
This is because that metabolites found in the lung tissue are likely responsible for the
biological activities observed in the lung. HPLC profiles of lung tissue samples from
mice fed with or without 5DN were shown in figure 3.4. Lung tissue samples from the
positive control group showed no apparent peaks, whereas there were three major peaks
shown in the chromatogram of the lung tissue sample from mice fed 0.05% of 5DN. By
comparing to the chromatogram of chemical standards of 5DN and it metabolites, the 3
peaks were identified as M1, M2, and 5DN at retention times of 11.9, 13.6 and 14.9 min,
respectively. M3 was not detected in the lung tissue. The levels of 5DN, M1 and M2 in
the lung tissue were shown in table 3. The results suggested that there were considerable
amount of 5DN (1.56 nmol/gram of tissue) and its metabolites M1 (0.034 nmol/gram of
tissue) and M2 (0.15 nmol/gram of tissue) distributed in lung tissue after dietary
consumption of 5DN. This is very useful information because it demonstrated the
presence of metabolites M1 and M2 in the lung tissues, indicating the potential role of
these metabolites in inhibiting lung tumorigenesis.
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Figure 3.4 Representative HPLC profile of lung tissue from positive control group
(upper) and from 0.05% 5DN treated group (bottom). Lung tissue Samples were detected
by electrochemical detector at 300mV. There is no apparent peak in chromatogram of
positive control group. 3 major peaks in chromatogram of 0.05% 5DN treated group were
identified as 5DN (retention times at 14.9 min) and its metabolites M1 (retention times at
11.9 min) and M2 (retention times at 13.6 min)

Table 3.3 Quantification of 5DN and its metabolites in the lung tissue of 5DN-fed mice
Concentration (nmol/gram

Percentage among

tissue)

compounds (%)

5DN

1.56 ± 0.26

89.3

M1

0.034 ± 0.018

1.9

M2

0.15 ± 0.076

8.8

Compound

5DN and its metabolites were extracted by ethyl acetate from lung tissue homogenate of mice fed
with 5DN, then quantified by HPLC. Concentration values were presented as mean ± SEM (n=5)
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3.3.4 5DN and its metabolites induce cell cycle arrest and apoptosis in lung cancer
cell
Due to the fact oral administration of 5DN resulted in the presence of 5DN as well
as its metabolites M1 and M2 in the mice lung tissues, we hypothesized that the
metabolites might contribute to the inhibitory effects of dietary 5DN on lung
tumorigenesis. Our previous studies have demonstrated that 5DN metabolites possessed
potent inhibitory effects on the growth of two human lung cancer cell lines H1299 and
H460. However, to better understand the roles of 5DN metabolites in inhibiting
NNK-induced lung tumorigenesis, herein we studied the effects of 5DN and its
metabolites (M1 and M2) on the growth of human (A549) and mouse (CL13) lung cancer
cells. This is because that: (i) CL13 cells were derived from NNK-induced mouse lung
tumors, therefore, serve as an excellent in vitro cell culture model closely related to
NNK-induced mouse lung tumorigenesis; and (ii) A549, a human bronchioalveolar
carcinoma cell line, was widely used in studies related to tobacco carcinogen
NNK-induced lung tumorigenesis and associated carcinogenic mechanisms(130,131).
Therefore, the effects of test compounds on A549 and CL13 cells may better represent
what might occur during NNK-induced lung tumorigenesis. As shown in Figure 3.5, 5DN
and its metabolites inhibited the growth of both human and mouse lung cancer cells in a
dose-dependent manner. Interestingly, the metabolites M1 and M2 showed stronger
inhibitory effect than 5DN. The IC50 value of 5DN after 72 hours of treatment was 21.8
µM in CL13 cells, however, the IC50 values of M1 and M2 were 1.3 µM and 5.6 µM,
respectively. The results indicated that M1 and M2 were 16.5-fold and 3.9-fold stronger
than 5DN in inhibiting the growth of CL13 cells, respectively. The similar results were
also observed in A549 cells. The much higher potency of M1 and M2 than 5DN
suggested that they might play important roles in inhibiting lung tumorigenesis even their
tissue levels in the lung were lower than that of 5DN in mice.
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Figure 3.5 inhibitory effects of 5DN and its metabolites (M1 and M2) on the growth of
A549 human (A) and CL13 mouse lung cancer cells (B). A549 and CL13 cells were
seeded in 96-well plates and treated with serial concentrations of 5DN, M1 and M2. After
72 hours of treatments, cell viability was quantified by MTT assay as described in
method section. Data represented mean ± SD (n=6), and asterisks indicated the statistical
significance in comparison with the control cells (p<0.01)

To further understand the mechanisms by which 5DN and its metabolites inhibit the
cancer cell growth, cell cycle and apoptosis analysis was conducted on cancer cells
treated with 5DN, M1 or M2 at concentrations that produced similar degree of growth
inhibition on the cells. As showed in Figure 3.6, in A549 cells, 5DN at 20 µM and M2 at
10 µM significantly increased cell population in G1/G0 phase, and decreased cell
population in S and G2/M phase, with M2 at much lower concentration led to higher
G1/G0 cell population than 5DN. In contrast, M1 at only 2 µM significantly increased
G2/M cell population of A549 cells. In CL13 cells, treatment with 5DN at 20 µM
increased cell population in G2/M phase, while much more increase in G2/M cell
population was caused by M1 at much lower concentration (1 µM). M2 at 5 µM modestly
increased both G1/G0 phase and G2/M phase cell population. These results demonstrated
that 5DN, M1 and M2 caused cell cycle arrest at different phases, and these effects were
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cell type specific as well. It is important to realize that small difference in the chemical
structures of these compounds led to high degree of difference in their potency and mode
of actions. Future research is warranted to investigate the combined effects of 5DN and
its metabolites in tumor inhibition. This is because that the co-existence of these
compound in the lung tissue may led to favorable interaction among them to produce
enhanced tumor inhibition as they may have complementary mode of actions.
Figure 3.6 Effects of 5DN and its metabolites (M1 and M2) on cell cycle progression of
A549 human (A) and CL13 mouse lung cancer cells (B). Cells were seeded in 6-well
plates then treated with 5DN, M1 and M2. After 24h treatments, cells were harvested and
subjected to cell cycle analysis as described in methods section. All data represented
mean ± SD (n=3). Statistical analyses were conducted among control and treated groups
in G0/G1, S and G2/M phases separately, and different notations in the bar charts
indicated statistical significance (p<0.01) according to ANOVA analysis followed by
Tukey HSD test.
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To determine the extent to which cellular apoptosis contributed to the growth
inhibition by 5DN and its metabolites, we quantified apoptosis in lung cancer cells
treated by these compounds by Annexin-V/PI double staining assay using flow cytometry.
As shown in Figure 3.7, 5DN and its metabolites increased both early and late apoptotic
cells in A549 cell line. However, M1 and M2 at lower concentrations showed much
stronger effects that 5DN. 5DN at 20 µM increased early apoptotic cell population by
4-fold compared to the control. M1 at 2 µM and M2 at 10 µM dramatically increased
early apoptotic cells by 42.8-fold and 24.2-fold compared to the control, respectively.
Moreover, M1 and M2 also increased late apoptotic cell population by 5.5-fold and
9.5-fold compared to the control, respectively, whereas 5DN only increased it by
1.75-fold compared to the control. The results also showed that M1 at 2 µM, M2 at 10µM
induced total cellular apoptosis that were 22.2-fold and 5.9-fold stronger than that
produced by 5DN at 20 µM, respectively. Similar trend was also observed in CL13
mouse lung cancer cells. Overall, M1 and M2 showed much stronger potency in inducing
cellular apoptosis in both human and mouse lung cancer cells than their parent compound
5DN. Again, these findings suggested that M1 and M2 might play important roles in
inhibiting lung tumorigenesis by inducing apoptosis.

Figure 3.7 Effects of 5DN and it metabolites (M1 and M2) on apoptosis of A549 human
(A) and CL13 mouse lung caner cells (B). Cells were seeded in 6-well plates then treated
with different concentrations of 5DN, M1 and M2. After 48 hours of treatments, cells
were collected and subjected to apoptosis analysis described in methods section. All data
represented mean ± SD (n=3), and different notations in the bar charts indicated statistical
significance (p<0.01) according to ANOVA analysis followed by Tukey HSD test.
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3.3.5 5DN and its metabolites modulated key signaling proteins related to cell
proliferation and apoptosis.
To further elucidate the molecular mechanisms of the inhibitory effects caused by
5DN and its metabolites on lung cancer cells, we examined their effects on the expression
of key proteins related to cell cycle progression and apoptosis in both human and mouse
lung cancer cells. Cell cycle related proteins p21Cip1/Waf1 and p53 were analyzed after 24
hours of treatment while apoptosis related proteins cleaved caspase-3 and cleaved PARP
were analyzed after 48 hours of treatment. Our results demonstrated that 5DN (20 µM)
and its metabolites M1 (2 µM in A549 cells, 1 µM in CL13 cells) and M2 (10 µM in
A549 cells, 5 µM in CL13 cells) caused extensive changes in these signaling proteins
(Fig. 3.8). In both cell lines, 5DN, M1 and M2 significantly increased expression levels
of p21Cip1/Waf1 and p53, except that 5DN only caused moderate increase in p21Cip1/Waf1
expression level in A549 cells, and M2 slightly increased p53 expression level in CL13
cells. The loss of cell cycle regulation is one of distinct features of cancer cells.
p21Cip1/Waf1 is a key inhibitory protein of Cip/Kip family which bind to CDK alone or to
the CDK-cyclin complex to regulated CDK activity and thus control the cell cycle
progression(132). p53 is a tumor suppressor which has a broad range of cellular functions
and plays important roles in inhibiting carcinogenesis(133) by inducing cell cycle
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arrest(134), cellular apoptosis(135), and DNA repair(136). Increased expression of p53
can result in G2/M cell cycle arrest by downregulating of both cyclin B1 and
Cdc2(134,137). Moreover, the expression of p21Cip1/Waf1 is under transcriptional control
by the p53 tumor suppressor gene. The p21 gene promotor contains a p53-binding site
which allows p53 to transcriptionally activate the p21 gene(138). The p53-mediated
upregulation of p21Cip1/Waf1 inhibits the activity of Cdk2- and Cdk4-cyclin complexes,
thereby causing cell cycle arrest at G0/G1 phase. The p21Cip1/Waf1 can also inhibit
Cdc2-cyclin B complexes and PCNA, interfering with PCNA-dependent DNA
polymerase activity, thereby inhibiting DNA replication and modulating DNA repair
processes(139). One or both of these actions can contribute to a G2/M cell cycle arrest
following ectopic p21Cip1/Waf1 expression or DNA damage(140,141). Our immunoblotting
results illustrated that the cell cycle arrest (G0/G1 or G2/M) in A549 and CL13 cells
caused by 5DN, M1 and M2 were associated with p53-depended induction of p21Cip1/Waf1.
In A549 cells, 5DN treatment has moderated effects in increasing p21Cip1/Waf1 expression
level, however it resulted in a significant increase of p53 expression. The induction of
p53 will stimulate the transcription of different genes including Mdm2 and Bax along
with p21Cip1/Waf1, which may contribute to the G0/G1 cell cycle arrest caused by 5DN.
Figure 3.8 Effects of 5DN, M1 and M2 on cell cycle and apoptosis related key proteins
in human A549 (A) and mouse CL13 (B) lung cancer cells. Cells were seeded in 15cm
culture dishes for 24 hours then treated with 5DN, M1 and M2 at different concentrations.
After another 24 or 48 hours of incubation, cells were collected for immunoblotting as
described in method section. The number underneath the blots represent band intensity
(normalized to β-actin, means of three independent experiments) measured by Image
Studio software. The SDs (all within ±15% of the means) were not shown. β-Actin was
used as an equal loading control. Asterisks indicated statistical significance in comparison
with control (p<0.05, n=3)
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Research has shown that apoptosis and the genes that control it have a profound
effect on the malignant type. It is now clear that disrupting apoptosis may lead to tumor
initiation, progression and metastasis(142). Thus triggering apoptosis has become one
important strategy for cancer prevention. The central engines of apoptosis are the
caspases, cascades of cysteine aspartyl proteases that implement cell death by cleaving a
variety of intracellular substrates that trigger programmed cell death(143). Activation
(cleavage) of caspase-3 can lead to the activation (cleavage) of other effector proteins,
such as poly ADP ribose polymerase (PARP), which ultimately trigger apoptosis by
interfering chromatin condensation and DNA fragmentation(144). We here found that
5DN, and its metabolites M1 and M2 intensively activated caspase3 as well as its final
protein target PARP in both A549 and CL13 cells. Moreover, M1 and M2 showed much
stronger effect in terms of inducing activation of caspase-3 and PARP when compared to
its parent compound 5DN. These results were consistent with the effects of 5DN, M1 and
M2 on cellular apoptosis (Fig. 3.7). Overall our findings demonstrated that M1 and M2 at
lower concentrations showed similar or stronger effects on key signaling proteins related
with cell cycle progression and apoptosis in comparison with that of 5DN, suggesting
their potential roles in inhibiting lung tumorigenesis.
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3.4 Conclusion
In the present study, we showed that dietary administration of 5DN, a unique
polymethoxyflavone from citrus fruit, significantly inhibited NNK-induced lung
tumorigenesis in female A/J mice. To our knowledge this is the first demonstration of the
chemopreventive effect of 5DN against lung tumorigenesis induced by cigarette
carcinogen in mice. We also, for the first time, identified and quantified two major
metabolites of 5DN in the lung tissue of 5DN-fed mice, namely M1 and M2. Furthermore,
we demonstrated that these metabolites, M1 and M2 exhibited much stronger anti-cancer
effects than 5DN. This was evidenced by their superior effects in inhibiting the growth of
both human and mouse lung cancer cells, inducing cell cycle arrest, triggering apoptosis
and modulating key signaling proteins. These findings strongly suggested that M1 and
M2 could significantly contribute to the observed inhibitory effects of dietary 5DN on
lung tumorigenesis in NNK-treated mice. In conclusion, this study provided a solid
scientific basis for using 5DN as a potential chemopreventive agent against lung
tumorigenesis in human.
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CHAPTER 4
COMBINATION TREATMENT OF NOBILETIN AND ATORVASTATIN
SYNERGISTICALLY INHIBITS NNK-INDUCED LUNG TUMORIGENESIS IN
MICE
4.1 Introduction
Atorvastatin (commercially sold as Lipitor® or Torvast®, ATST) is one of the
recognizable statin drugs which is capable to lower the total cholesterol levels and reduce
density lipoproteins levels by inhibiting the activity of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis
pathway(145). In addition to the potent efficacy of statins in reducing cardiovascular
diseases risk and the relatively low adverse effects, statins are also found to exert
pleiotropic effects that have lead to their widespread utilization for other chronic diseases
including cancers(17). Various types of tumor, including lung carcinoma, colon
carcinoma, hepatocellular carcinoma, lymphoma, and leukemia, have been found to
increase HMG-CoA activity(146–148). The cancer preventive effect reported for statins
is mainly attributed to their inhibition of HMG-CoA activity, which subsequently inhibits
the isoprenylation of small G-proteins, modulation of membrane protein trafficking and
post-translational modification of proteins. Protein prenylation (farnesylation or
geranylgeranylation) is vital for cytosol-to membrane translocation of small G proteins
including RhoA to exert their location-specific activities involving in the control of
cellular adhesion, proliferation, and survival(149,150,97). Recently, statins have been
reported to inhibit different types of cancer cells growth(151,89,93,152–156).
Epidemiology studies also revealed that the use of statin might be associated with
decrease mortality of cancer patients(157–162).
Polymethoxyflavones (PMFs) are a unique class of flavonoid compounds that
exclusively found in the citrus peels such as sweet oranges (Citrus sinensis) and
mandarin oranges (Citrus reticulata). Studies have showed that they exhibit
anti-carcinogenic(15,110,123,163), anti-inflammatory(54,108), anti-atherogenic(68,69),
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and anti-fungus properties(164). Nobiletin (NBT) is one of the most abundant PMFs
found in the orange peels(52) which is also among the effective citrus flavanoids at
inhibition of human cancer cell proliferation (165). Recently, we and other groups have
reported the growth inhibitory activities of NBT against lung(9), colon(16,123), and
breast cancer cells(166,167).
At present, lung cancer is the leading cause of death in the United States(101).
Recently, the concept of using combination strategy of bioactive dietary components with
modern therapeutic drugs for cancer chemoprevention has gained much attention. Despite
the potent anticancer activities of each individual cancer treatment drugs, the use of only
a single compound often requires a relatively high dose, which is usually linked with
many side effects. Combination of two or more agents targeting at multiple sites or have
distinct mechanism actions have been suggested as a promising approach to enhance
efficacy and diminish toxicity caused by using individual drug treatment. Moreover, our
previous study reported the synergistic activities of atorvastatin and green tea
polyphenols in inhibiting lung tumorigenesis in NNK injected mouse model as long as in
human NSCLC cells(20).
Taken together, we herein investigated the possible synergistically inhibitory
activities produced by the combination of NBT and ATST on the NNK-induced lung
tumorigenesis in A/J female mice.
4.2 Materials and methods
4.2.1 Animals, diets, and experimental design
This animal experiments were done under the Institutional Animal Care and Use
Committee of University of Massachusetts Amherst approved protocol (#2014-0079).
Five-week-old female A/J mice (18-22g) were obtained from The Jackson Laboratory
(Bar Harbor,ME) and housed in plastic cages (six mice/cage), under controlled conditions
of 22 ± 2 °C and 50 ± 10% humidity in a fixed day/night cycle (12 hrs light). The animals
were free access to water and maintained in a basal AIN-76A diet for 1 week for
acclimation(168,169). Then the mice were received an i.p. injection of NNK (100mg/kg

45

body weight) or saline (vehicle control). 2 days after NNK injection, they were given
NBT alone (0.025% or 0.05% in diet), ATST alone (200 or 400 ppm in diet), or 0.025%
NBT plus 200 ppm ATST mixed in the diet for 16 weeks. The vehicle control mice were
given basal diet. Body weight was recorded weekly. After a treatment period of 16 weeks,
all mice were sacrificed. Liver and spleen were harvested and weighted, intact lungs were
excised, inflated, infused with 10% neutral buffered formalin, transferred within 2 days in
80% alcohol, and evaluated under a dissecting microscope for pulmonary surface tumors.
The results were present as the percent of mice with lung tumors (incidence), the mean
number of tumors per mouse ± SEM (Multiplicity) and the mean tumor burden ± SEM
(calculated according the formula: V=4/3πr3; r=radius calculated from the average of the
longest and shortest diameters).
4.2.2 Tumor Histology
The formalin-fixed lung samples were then embedded in paraffin, sectioned in serial
5-µm sections. The tissue slides from the serial sections were stained with hematoxylin
and eosin (H & E) for histopathological analysis. Lung proliferative lesions were
diagnosed as alveolar cell hyperplasia and adenoma according to established
criteria(119).
4.2.3 Immunohistochemisty
Immunohistochemisty was conducted on the lung tissue sections by using specific
antibodies to analyze the localization and levels of the positive staining. Tumor cell
proliferation in the lung was evaluated by measuring the positive staining against
proliferative cell nuclear antigen (PCNA). Cellular apoptosis were determined by staining
with antibodies against cleaved caspase-3 (C-C-3). Briefly, paraffin-embedded sections
were deparaffinized then subjected to antigen retrieval through heating in sodium citrate
buffer for 20 min in an automated epitope recovery device (Lab vision PT Module,
Thermo Scientific). Endogenous peroxidase was quenched in 3% H2O2 in PBS and the
non-specific bindings sites were blocked by incubation with Odyssey blocking buffer.
The sections were then incubated with antibodies against PCNA (Dakom Denmark) or
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C-C-3 (Cell Signaling Technology, Beverly, MA, USA) overnight at 4 °C. Proper
biotinylated secondary antibody and avidin-biotin peroxidase complex were then applied
to the sections, followed by the chromogen 4-diaminobenzidine (Dako, Carpinteria, CA,
USA). Sections were then counterstained with hematoxylin for 2 minutes. Positive
expression of PCNA and C-C-3 was observed under light microscope.
4.2.4 Statistical analysis
Two-tailed Student’s t-test was used to compare simple comparisons between two
groups. Analyses of variance (ANOVA) model was used to compare the differences
among multiple groups followed by Tukey’s Range Honesty Significant Difference
(Tukey’s HSD) post-hoc test. In animal studies, tumor incidence was analyzed by
Fisher’s exact probability test. The interaction between two agents (additive, synergistic,
or antagonistic) was assessed by the method of model-free tests, which is based on the
method of isobologram analysis by Laska et al.(170). We assumed the expected response
with the combination, g (NBT 0.025%, ATST 200ppm), was a monotone, nondecreasing
and continuous function (g was defined as the tumor multiplicity or tumor burden in
animal model). Synergistic, additive or antagonistic effect was defined if g (NBT 0.025%,
ATST 200ppm) was higher than, equal to, or lower than g(NBT 0.05%, ATST 0) and
g(NBT 0, ATST 200ppm), respectively.
4.3 Results
4.3.1 General observation of experiment animals
All mice survived after 16 weeks of treatment. No significant differences in diet
and water consumption were noticed, and no apparent behavioral or appearance were
observed among the groups, suggesting that there is no noticeable toxicity by NBT, ATST
or NBT/ATST combination treatment. However, the mice in 400 ppm ATST group and in
half dose combination group showed lower body weights compared with those in other
groups (significantly lower in comparison with 0.05% NBT groups, p < 0.01) at the
terminal point (Fig 4.1). This may be partially due to the lowered body fat weight caused
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by ATST(20). To further evaluate the toxicity of treatments, we measured the weight and
relative weight (%RW) of liver and spleen. As showed in Tab 4.1, there was no
significant difference in weight or relative weight of spleen among all groups. However,
the relative liver weight of mice from NNK control groups was significantly lower than
those from saline control, 400 ppm ATST group and NBT/ATST combination group.
According to previous studies, NNK was reported to cause decrease in liver weight in
mice(120,125). And our result showed that ATST or NBT/ATST treatment might
ameliorate this effect caused by NNK. Overall, the oral administration of NBT, ATST
alone, or NBT/ASTS combination did not exhibit toxicity in female A/J mice.

Figure 4.1 Effects of oral administration of NBT, ATST, or NBT/ATST combination on
body weight of mice. NBT (0.025% or 0.5%), ATST (200 or 400 ppm), and NBT (0.025%)
plus ATST (200ppm) in diet were given to the mice two days after NNK injection until the
termination of the experiment (16 weeks). The body weights were recorded weekly.
Significant reduction of body weights by ATST (400ppm) and its half dose combination
with NBT was observed. (P<0.01, One-way ANOVA analysis followed by Tukey’s HSD
Test).
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Table 4.1 Final liver, relative liver, spleen and relative spleen weights
Group

No.of mice

Liver

Spleen

W (g)

% RW

W (g)

% RW

Saline Control

10

1.04±0.03

4.38±0.09ab

0.078±0.002

0.32±0.01

NNK Control

20

0.92±0.02

3.92±0.09c

0.070±0.004

0.3±0.02

0.025% NBT

20

0.97±0.03

4.03±0.08bc

0.065±0.002

0.27±0.01

0.05% NBT

20

1.03±0.03

4.27±0.11abc

0.068±0.002

0.28±0.01

200 ppm ATST

20

0.97±0.02

4.18±0.07abc

0.063±0.002

0.27±0.01

400 ppm ATST

20

1.04±0.20

4.62±0.08a

0.065±0.002

0.29±0.01

0.25% NBT + 200 ppm ATST

20

0.99±0.03

4.40±1.12ab

0.066±003

0.29±0.01

All values represent mean ± SEM, and the different letters in the table indicated statistically
significant difference (P<0.05) according ANOVA analysis followed by Tukey’s HSD test.

4.3.2 Inhibition of NNK-induced lung tumorigenesis by NBT, ATST, and their
combination
We found that all the NNK-treated mice developed lung tumors at the termination
point in this study. The gross tumors were generally composed of well-differentiated cells
in a solid or papillary pattern (figure 4.2A), and were further identified as solid adenoma
from the histological analysis according to established criteria(119). No tumor was found
in vehicle control group. As shown in Tab 4.2, all the dietary treatments did not show
significantly effects on tumor incidence. Individual treatment with NBT or ATST slightly
decreased the tumor multiplicity but without statistic significance (p>0.05). However,
NBT (0.05%) or ATST (200 or 400 ppm) alone significantly reduced the tumor burden
(29.4% reduction for 0.5% NBT, 27.6% and 32.0% reduction for 200 ppm and 400 ppm
ATST respectively, P<0.05) in comparison with NNK control group. Most interestingly,
we found that the NBT/ATST combination at half dose significantly reduced both tumor
multiplicity and tumor burden (by 40.4% and 59.7%, respectively, P<0.05) compared to
NNK control group. Base on these results, we demonstrated that the inhibitory effect of
NBT/ATST combination at half dose on lung tumorigenesis was significantly stronger
than the effects produced by either NBT or ATST alone in this model. The isobologram
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analysis suggested a significant synergistic effect of NBT/ATST combination in the
inhibition of tumor multiplicity (P=0.0008) and tumor burden (P=0.0006).
Table 4.2 Effects of oral administration of NBT, ATST, or NBT/ATST combination on
NNK-induced tumorigenesis in female A/J mice
Tumor

Tumor

Tumor

Incidence (%)

Multiplicity

Burden (mm3)

10

0

0

0

NNK Control

20

100 (20/20)

15.6±1.0a

5.44±0.52a

0.025% NBT

20

100 (20/20)

12.4±0.8a

4.09±0.26ab

0.05% NBT

20

100 (20/20)

12.1±0.8b

3.84±0.32b

200 ppm ATST

19

100 (20/20)

12.5±0.8a

3.94±0.44b

400 ppm ATST

20

100 (20/20)

11.6±0.8b

3.70±0.26b

0.025% NBT + 200 ppm ATST

20

100 (20/20)

9.3±1.0c

2.19±0.26c

Group

No.of mice

Saline Control

Tumor burden was calculated as the sum of the tumor volume of all tumors in one mouse. All
values represent mean ± SEM, and the different letters in the table indicated statistically significant
difference (P<0.05) according ANOVA analysis followed by Tukey’s HSD test.

4.3.3 Modulation of PCNA, cleaved caspase-3 by NBT, ATST, and their combination
in NNK-induced lung adenomas
To study the mechanisms of the inhibitory effects produced by NBT, ATST and
their combination, we examined their modulatory role during cell proliferation and
cellular apoptosis in NNK-induced lung adenomas. PCNA plays a critical role in cell
duplication by regulating DNA replication. The expression level of PCNA increased
during cell proliferation thus it is often used as a key marker of cell uncontrolled
growth(127). Hereby, the effects of NBT, ATST and their combination on proliferation
were assessed by PCNA labeling of cells (figure 2B). Quantification of PCNA staining
showed that NBT (0.05%) or ATST (400ppm) alone significantly decreased the
proliferation index by 36.8% (30.6±2.7 versus 48.4±3.8) and 30.0% (33.9±2.5 versus
48.4±3.8) respectively, when compared with the NNK control group. Moreover,
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combination of NBT (0.025%) and ATST (200ppm) showed a labeling index of 18.3±2.2,
reflecting a decrease in the proliferation index by 48%, suggesting that the inhibitory
effect of lung tumor cell proliferation produced by NBT/ATST combination at half dose
was much stronger than those produced by NBT or ATST alone at higher dose.
Cellular apoptosis of lung tumor was determined by anti-cleaved caspase 3
labeling (Figure 4.3D). Quantification results revealed that about 0.18% tumor cells
showed positive staining of C-C-3 in the NNK control group. 400 ppm ATST treatment
slightly increased the apoptotic index, but with no statistical significance. NBT treatment
at 0.05% dose increased the apoptotic cells to 0.30%, which is a 1.7-fold increase
compared with NNK control group. Markedly, combination of 0.025% NBT and 200 ppm
ATST significantly increased the apoptotic index by 2.9-fold (0.52% apoptotic cells),
suggesting the stronger effect on triggering cellular apoptosis by NBT/ATST
combination.
Figure 4.2 Effects of NBT, ATST, or NBT/ATST combination on immunohistochemical
staining of NNK-induced lung tumors for proliferation and apoptosis after 16 weeks
treatment. A, H&E staining of normal lung tissues, NNK-induced lung adenoma in a solid
gowth pattern and in a papillary growth pattern. B, immunohitochemistry with anti-PCNA
antibody in normal lung, NNK-induced adenoma, and adenoma in mice treated with
NBT/ATST combination. C, effects of NBT, ATST and their combination on the
proliferation index. Different letters indicated statistical significance (P<0.05) according
AMOVA analysis followed ty Tukey HSD test. D, immunohistochemistry with
anti-cleaved caspase-3 antibody in normal lung, lung adenoma, and adenoma in mice
treated with NBT/ATST combination. E, effects of NBT, ATST and their combination on
the apoptotic index. Different letters indicated statistical significance (P<0.05) according
ANOVA analysis followed by Tukey’s HSD test.
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4.4 Discussion
In this paper we found that NBT/ATST combination produced synergistic effects in
inhibiting NNK-induced lung tumorigenesis by suppressing tumor cell proliferation and
triggering cellular apoptosis. We previously demonstrated that NBT/ATST combination
synergistically inhibited NSCLC cells growth by inducing G0/G1 cell cycle arrest and
apoptosis, and these activities involving the EGFR/ERK/RhoA by inhibiting
cytosol-to-membrane translocation of RhoA. This is the first demonstration of the
inhibitory effect produced by such a combination on tumorigenesis and cancer cell
growth.
NBT is one of the most abundant polymethoxyflavones found in the peel of sweet
oranges(52,165), It was showed to exhibit protective activities against carcinogenesis
both

in

vivo

and

in

vitro,

including

gastric(171),

colon(12,13,62,123,166),

breast(166,167), and prostate cancers(13) by many mechanisms. NBT also was observed
to suppress cell adhesion, invasion, and migration abilities of human gastric
adenocarcinoma AGS cells at low concentration (2 µM)(172). NBT was also found to exert
anti-angiogenesis activities in both live transgenic zebrafish and human umbilical vein
endothelial cells(173). However, NBT treatments in our previous(9) and present studies at

high concentrations (> 30 µM) did not cause any significant change in cell proliferation,
cell cycle distribution, and apoptosis in all 3 human NSCLC cells suggesting that the
cytostatic activities of NBT could be cell-type specific.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, which is the rate-limiting enzyme in cholesterol biosynthesis pathway. The
inhibition of HMG-CoA reductase in turn results in the reduced level of mevalonate and
the formation of its downstream products including ubiquinone, cholesterol, dolichol and
most importantly, the lipid isopreniods such as farnesyl pyrophosphate (Fpp) and
geranylgeranyl pyrophosphate (GGpp) which both of them play the crucial roles in
post-translational modification of membrane related proteins related to cell proliferation,
including Ras and Rho proteins. Both Fpp and GGpp prenylate proteins help facilitate
protein translocation from cytosol to membrane. They also regulate and promote
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protein-protein, and protein-membrane interactions and functions(149). The subsequent
production of both GGpp and Fpp could be suppressed by inhibiting activity of
HMG-CoA reductase. Although Fpp is the immediate precursor of GGpp, the addition of
Fpp into the system with statins typically does not restore GGpp and turn around statins
actions including their growth inhibitory effects because isopentenyl pyrophosphate,
which is the upstream process prior to Fpp synthesis is already depleted by blocking
HMG-CoA reductase caused from statins’ activity, is required in order to synthesize
GGpp from Fpp. Therefore, isopentenyl pyrophosphate is not available for converting
Fpp into GGpp and hence, GGpp cannot be restored by adding Fpp, but can be refreshed
by

adding

mevalonate

which

sits

at

the

apex

of

the

pathway(174,175).

Post-translational prenylation by Fpp (farnesylation) or GGpp (geranyl-geranylation) is a
critical step that helps anchor the small G-proteins, such as Rho and Ras families, to
membrane in order to perform their functions.
Several studies have also reported the potential enhancement of lung cancer
inhibition by using ATST in combination with pharmacological or dietary compounds in
vivo. Lu et al. showed that the low-dose combination of green tea polyphenols and ATST
synergistically reduced both the tumor multiplicity and tumor burden induced by NNK in
A/J mice, possibly through enhanced apoptosis, while the individual agents were not
effective in inhibiting lung tumorigenesis(20). Pereira et al. demonstrated that the
combined treatment of ATST and suberoylanilide hydroxamic acid (SAHA) potently
reduced the multiplicity of lung tumors induced by vinyl carbamate in A/J mice while
treatment of ATST alone did not. Moreover, the combination also inhibited lung tumor
induced by 4-(methylnirtrosamino)-1-(3-pyridyl)-1-butanol (NNK) in strain A/J mice
model with the great efficacy while the treatment of ATST alone did not cause any
significant change. Furthermore, combination of SAHA and ATST also decreased the
multiplicity of lung tumors induced by 1,2-dimethylhydrazine in Swiss-Webster mice
while ATST alone did not(22). Chen et al also demonstrated that the combination of
ATST and interferon-γ resulted in a synergistic inhibition of both in vitro (H358 and
H596 NSCLC growth) and in vivo (H358 and H596 xenograft study)(176).
Based on our study of NNK-induced lung tumorigenesis model and the
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isobologram analysis by Laska et al.(170), we indicated that the low doses of NBT and
ATST produced synergistic inhibition on lung tumor burden and multiplicity. And this
inhibitory effect was associated with the suppression of cell proliferation and
enhancement of cellular apoptosis in adenomas as determined by PCNA and cleaved
caspase-3 immunohistochemistry respectively. In this study, we mainly focused on the
postinitiation promotion stage of lung tumorigenesis (on the formation of the adenoma).
So we started our treatment 2 days after the NNK injection to avoid the influence of
tumor initiation by our compounds. Therefore, We did not observed significant effect on
tumor incidence by NBT, ATST or their combination.
Metabolites of dietary components could also exert their biological effects, and
are of importance to investigate their mode of actions. NBT will be undergone extensive
biotransformation after being absorbed into our body. We and others reported that NBT
could

be

converted

to

3´-demethylnobiletin,

4´-demethylnobiletin,

and

3´,4´-didemethylnobiletin(75,76,109,177). And these metabolites of NBT were able to
promote superior biological activities than those of NBT produced(25,109) We recently
have found that 4´-demethylnobiletin was capable to synergize with ATST to exert
anti-cancer activities against lung and colon cancer (data not shown), therefore; it is
interesting to study if metabolites of NBT were able to synergize with ATST to produce
the greater anticancer effects on NSCLC.
In conclusion, we found that NBT/ATST half dose combination synergistically
produced much stronger inhibition on lung tumor multiplicity and tumor burden than
those produced by individual treatment with NBT or ATST at full dose. The inhibition
was associated with suppressed cell proliferation and enhanced apoptosis in adenoma as
determined by immunohistochemistry.
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CHAPTER 5
CHEMPOREVENTION OF COLITIS ASSOCIATED COLORECTAL
CARCINOGENESIS BY 5-DEMETHYLNOBILETIN AND ITS COLONIC
METABOLITES

5.1 Introduction
Colorectal cancer (CRC) is a major health care problem with the third highest rates
of morbidity and mortality in the United States(2,178). Chronic inflammation is
implicated as a risk factor for colorectal carcinogenesis due to their effects on enhancing
proliferation of malignant cells, promoting angiogenesis, boosting tumor metastasis, and
altering tumor response to chemotherapeutic agents(179), therefore is considered to be a
direct cause of colitis-associated cancer in numerous experimental models and
humans(180,181). The correlation between colitis and CRC has been broadly accepted.
Indeed, clinical research had showed that patients with inflammatory bowel disease (IBD)
such as Crohn’s disease and ulcerative colitis had 2- to 3-fold higher risk of developing
CRC compared to the general population(182,183), creating an urgent need for more
efficacious

strategies

targeting

colorectal

carcinogenesis,

including

chemoprevention(184).
Epidemiological studies have indicated an inverse correlation between the intake of
fruits/vegetables and human colon cancer. And this can be attributed to the bioactive
components existed in these fruits/vegetables(185,186). Citrus fruit contains several
chempreventive

compounds

against

cancers.

Among

them,

5-demethylated

polymethoxyflavones is a unique subclass of polymethoxyflavones (PMFs) that have
been recently isolated and documented to have numerous health-beneficial activities,
including

anticancer

and

anti-inflammation

ones(7,187).

For

example,

5-demethylnobiletin (5-hydroxy-6,7,8,3’,4’-pentamethoxyflavone, 5DN), which is one of
the most abundant 5-demethylated PMFs from citrus fruit, has shown potent inhibitory
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effects against multiple cancer cells and lung xenograft tumors(16,78,188).
Accumulating evidence has suggested that biotransformation is crucial for the
biological effects of orally administered compounds. Because the metabolites generated
in the body through biotransformation may have different chemical structures, which may
lead to similar or even stronger bioactivities in comparison with their parent compounds.
Therefore, to better understand the in vivo efficacy of dietary compounds, it is necessary
to investigate the biological activities of their metabolites in body. Previously, we have
demonstrated the chemopreventive effect of 5DN on NNK-induced lung tumorigenesis in
mice, and this effect was strongly associated with its two major metabolites in lung.
However, there is no scientific information about the in vivo efficacy of 5DN on
colitis-associated colon cancer. To better understand the chemopreventive activities of
5DN and the potential contribution of biotransformation, we systematically investigated
the inhibitory effect of dietary 5DN on azoxymethane (AOM) induced and dextran
sulfate sodium (DSS) promoted colon carcinogenesis in CD-1 mice, identified and
quantified the major colonic metabolites of 5DN in mice, and demonstrated the inhibitory
effects of these metabolites on human colon cancer cells.
5.2 Materials and methods

5.2.1 Animals, diets, and experimental design
This experimental protocol was approved by Institutional Animal Care and Use
Committee of University of Massachusetts Amherst (#2014-0079). Approximately
6-week old male CD-1 mice were obtained from Charles River Laboratory (Wilmington,
MA). After one-week of acclimation to the animal facility, mice were randomly assigned
to three experimental groups (negative control group, positive control group, and 5DN
group, 20 mice each) and placed on an AIN-93G diet (Figure 5.1). Then the animals in
positive control group and 5DN group received a single intraperitoneal injection of AOM
(12 mg/kg body weight) in saline, and animals in negative group received same volume
of saline. One week after AOM injection, 1.5% DSS (molecular weight: 36 000-50 000,
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MP Biomedicals, Solon, OH) was administered in the drinking water for 4 days followed
by one week of regular water for recovery, and this cycle was repeated four times
(negative control group received regular drinking water without DSS). Starting one week
after AOM injection, negative and positive control groups were fed with AIN-93G diet,
while 5DN group was fed with AIN-93G diet containing 5DN (0.05 wt% in diet) until the
end of the experiment. The body weight was recorded weekly. All mice were humanely
sacrificed via CO2 asphyxiation 20 weeks after AOM injection. The liver and spleen were
removed and weighted. At necropsy, after measuring the length, the colons were opened
longitudinally, flushed with PBS (pH 7.4) and weighted. The number of tumors was
counted, and the size of the tumors was measured using a caliper. The tumor volume was
determined using the formula V (mm3)=0.5 × (length × width × width) as reported. Then
the colons were cut into tow halves along the main axis. Half of the colon was fixed in 10%
buffered formalin (pH 7.4) for 24 h for histopathological and immunohistochemical
analysis. The other half was sored at -80 °C for ELISA, qRT-PCR, and HPLC analysis.
Figure 5.1 Experimental design to determine the inhibitory effect of 5DN on
AOM/DSS-induced colon carcinogenesis in mice model. Detailed information was
provided in Materials and methods.
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5.2.2 Histopathological hand immunohistochemical analysis
The fixed colon tissue was dehydrated, embedded in paraffin, sectioned, mounted on
glass slides and stained with hematoxylin and eosin as we previously described(122). The
histological alterations such as mucosal dysplasia, and carcinoma were evaluated under a
microscope according to the criteria previously described(189,190). In brief, colonic
mucosal dysplasia is characterized by elongated, crowded and pseudostratified nuclei.
Carcinoma was defined as a high-grade dysplasia of colonic mucosa that had invaded
beyond the muscularis mucosa and into the submucosa. Immunohistochemisty staining
was performed on the colon tissue sections as we previously described(122). Cell
proliferation in the colon tissue was determined by positive staining of proliferating cell
nuclear antigen (PCNA) and Ki-67. Cellular apoptosis was determined by staining with
antibodies against cleaved caspase-3 (Cell Signaling Technology, Beverly, MA). Colonic
inflammation was measured by staining with antibodies against inducible nitric oxide
(iNOS).
5.2.3 ELISA and real-time qRT-PCR analysis
Colonic mucosa were scraped and homogenized in a phosphate buffer solution
containing 0.4 M NaCl, 0.05% Tween-20, 0.5% BSA, 0.1 mM benzethonium, and 1%
protease inhibitor cocktail (Boston Bioproducts, Ashland, MA). Then the homogenates
were centrifuged at 10 000 g for 30 min at 0 °C. The supernatant was collected and used
for quantification of cytokines, i.e. IL-1β, IL-6, and tumor necrosis factor-α (TNF-α) by
ELISA kits (R&D Systerm, Minneapolis, MN) according to the manufacture’s
instructions. Real Time qRT-PCR analysis was performed as previously described(57).
The primer pairs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA)
with the following primers: IL-1β F: 5’-ACCTGCTGGTGTGTGACGTT-3’, R:
5’-TCGTTGCTTGGTTCTCCTTG-3’;

IL-6

5’-GAGGATACCACTCCCAACAGACC-3’,
GTTCATACA-3’;

TNF-α

F:

R:

5’-AAGTGCATCATCGTT

5’-AGCACAGAAAGCATGATC
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F:
CG-3’,

R:

5’-CTGATGAGAGGGAGGCCATT-3’;

β-actin

F:

5’-AAGAGAGGCATCCTCACCCT-3’, R: 5’-TACATGGCTGGGGTGTTGAA-3’(191).
The copy number of each transcript was calculated with respect to the β-actin copy
number, using the 2-ΔΔCt method(192).
5.2.4 Quantification of colonic 5DN and its metabolites by HPLC
Colonic mucosa samples were homogenized in methanol (50% in phosphate buffered
saline, pH=5.00) and then extracted with ethyl acetate for three times. Pooled ethyl
acetate fractions were dried under vacuum and reconstituted in 50% methanol.
Identification and quantification of 5DN and its metabolites were performed using HPLC
method as we previously described(77,124). 5DN, M1, M2, and M3, with purity greater
than 98%, were used as external standards and tangeretin (>98%) was used as an internal
standard. Tangeretin was purchased from Sigma-Aldrich (St. Louis, Mo). 5DN, M1, M2,
and M3 were synthesized as described previously(77,124).
5.2.5 Cell viability, cell cycle and cellular apoptosis analysis
The analysis of cell viability, cell cycle and apoptosis were conducted as we
previously described(16,110). In brief, human colorectal cancer cell lines, HCT116 and
HT29 (ATCC, Manassas, VA) were seeded at a density of 2500 cells/well in 96-well
plates. After 24 h incubation, cells were treated with treatments in serum complete media
for
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h.

The

cell

viability

was

then

determined

by

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay(16,110). For
cell cycle and apoptosis assay, cells were seeded at a density of 5×104 cells/well in 6-well
plates. After 24 h of incubation for cell attachment, cells were treated with different
treatments in serum complete media. After 24h or 48h, floating cells in media and
adherent cells were harvest and subjected to cell cycle and apoptosis analysis by flow
cytomety method.
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5.2.6. Immunoblotting
Cells were seeded in 150mm culture dishes. After 24h of incubation for cell
attachment, cells were treated with different treatments. After another 24 or 48 h, cells
were harvested, combined with floating cells, if any. Whole cell lysates were prepared
and then subjected to Western blotting analysis as we previously described. Colon tissue
was homogenized with RIPA lysis buffer (Tris-Hcl pH7.2, 25mM; SDS 0.1%; Triton
X-100 1%; sodium deoxycholate 1%; Nacl 0.15% M; ethylenediaminetetraacietic acid
(EDTA) 1mM) (Boston Bioproducts, Ashland, MA) containing 1% protease inhibitor
cocktail.
5.2.7. Statistical analysis
All data were presented as mean ± SD or mean ± SEM. Student’s t-test was used to
test the mean difference between two groups, whereas analysis of variance (ANOVA)
followed by Tukey HSD test was used for the comparison of difference among three or
more groups. Tumor incidence was analyzed by Fisher’s exact probability test. A p value
< 0.05 was considered statistically significant.
5.3 Results

5.3.1 General observation
Bloody and soft stool was observed in a few mice that received DSS treatment. In
positive control group mice, anal prolapse due to severe inflammation and tumor
development in the distal colon was observed as well. As shown in Table 5.1, the mean
body weight, liver and spleen weight did not significantly differ among the groups.
Weight/length colonic ratio is correlated with the severity of colitis and therefore is a
measurement indicative of colonic wall thickening, severity of inflammation and
neoplasia development(193). Our result showed that Dietary 5DN significantly prevented
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the shortening of colon length and decreased the elevated weight/length ratio caused by
AOM/DSS treatment. Histologically, there were no pathological alterations or lesions
suggesting toxicity of the 5DN in the main organs (liver, kidneys and spleen) of mice.
Table 5.1 Final body weight, main organ weights, and colon assessment of mice
Group

Negative control

Positive control

5DN treated

Body Weight (g)

50.66±1.42

48.12±1.62

49.28±1.61

Liver Weight (g)

2376.34±68.52

2262.86±92.74

2278.04±105.40

Spleen Weight (g)

236.65±33.56

230.60±30.12

212.78±26.20

Colon Length (mm)

96.82±2.64a

86.14±3.72b

95.98±2.92a

Colon W/L ratio (mg/mm)

3.68±0.30a

4.32±0.50b

3.76±0.28a

Tumor incidence

0a

100%b

65%c

Tumor multiplicity

0a

5.70±1.1b

2.5±0.5c

Tumor burden (mm3)

0a

13.50±2.3b

6.7±1.8c

Data are shown as the mean ± SEM. Different notation indicates statistical significance
for the comparison of difference among groups (p<0.05, n=20) using ANOVA followed
by Tukey HSD test

5.3.2 Dietary 5DN suppressed AOM/DSS-induced colonic tumorigenesis
We use AOM/DSS-treated mice model to determine the chemopreventive effects of
5DN on colitis-associated colon carcinogenesis. In this model, a single injection of a
colon carcinogen AOM in combination with cyclic administration of DSS in drinking
water resulted in the development of colitis, colorectal dysplasia, and cancer(194). At the
end of the experiment, mice in positive control group all developed colon tumors with a
multiplicity of 5.7 ± 1.1 (mice in negative control group showed no tumor). Dietary 5DN
significantly decreased the tumor incidence and multiplicity by 35% and 56% (5.7 ± 1.1
versus 2.5 ± 0.5), respectively. In parallel, tumor burden was decrease from 13.5 ± 2.3 in
positive control group to 6.7 ± 1.8 in mice fed 0.05% 5DN. Histologically, AOM/DSS
treatment resulted in significant alterations of colonic mucosa, including loss of crypts,
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infiltration of inflammatory cells in to

the lamina propria, formation of

dysplasia, and tumor development

(Figure 5.2). 5DN was able to reduce

the occurrence of AOM/DSS-induced tumor compared with positive control mice. The
colonic mucosa of 5DN-treated mice appeared to largely maintain the normal histological
characteristics. These findings demonstrated that dietary 5DN effectively prevent
colitis-associated colon carcinogenesis in mice.
Figure 5.2 Histological characterization of colonic mucosa and tumors of mice

5.3.3 Dietary of 5DN reduced cell proliferation, induced apoptosis, and decreased
the levels of proinflammatory cytokines in the colon of AOM/DSS-treated mice
One of the hallmarks of colon carcinogenesis is the uncontrollable cell proliferation.
The most reliable methods to examine colorectal cell proliferation are via the evaluation
of Ki67 and PCNA using immunostaining. Ki-67 and PCNA are closely correlated with
somatic cell proliferation. Thus, increased proliferation of colon epithelial cell, which
was characterized as hyperplasia, can be detected with the Ki-67 and PCNA proliferation
markers(127,195). Colonic sections of the positive control mice showed intense staining
of Ki-67 and PCNA (Figure 5.3), indicating a high cell proliferation rate. In contrast, the
positive staining of Ki-67 and PCNA was markedly inhibited by 46% and 59% in 5DN
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treatment group, respectively, suggesting a reduction in cell proliferation. A reduction in
tumor incidence is generally correlated to a decrease in cellular proliferation and/or
increase in apoptosis(196). Thus, the induction of apoptosis is a promising mechanism in
the chemoprevention of caner(197). Using cleaved caspase-3 (Figure 5.4), which is an
activated regulator of apoptosis, as a marker, we found higher amount of apoptotic cells
in the colonic tumors of 5DN-treated group than those of positive control group. These
results demonstrated that dietary 5DN significantly inhibited abnormal cell proliferation
and induced apoptosis in the colonocytes of AOM/DSS-treated mice, which is thought to
exhibit its chemopreventive efficacy against colon carcinogenesis.
It is widely accepted that over-expression of proinflammatory cytokines and/or
enzymes amplifies inflammatory cascade signaling, causes intestinal tissue damage, and
increases the risk of colorectal carcinogenesis(198)(199). We further investigated the
effects of 5DN on the AOM/DSS-induced expression of these proinflammatory factors in
colon by Immunohistochemistry and ELISA analysis. An intense staining of iNOS was
observed in the colon tissue of AOM/DSS-treated mice, indicating a high level of
inflammation (Figure 5.4). However, dietary 5DN significantly decreased the expression
of iNOS by %. ELISA analysis of colon mucusa samples shown that 5DN treatment
resulted in significant decreases in the levels of IL-1β and IL-6 by 78.2% and 76.6%,
respectively, when compared to those of the control group. We then determined the
effects of dietary 5DN on the mRNA expression of proinflammatroy cytokines by
real-time qRT-PCR analysis. As shown in Figure 5.5, the mRNA expression levels of
IL-1β and IL-6 in the colon mucosa of 5DN-treated mice were significantly reduced by
96.4% and 98.2%, respectively. Together, these results suggested that dietary 5DN
significantly inhibited the colitis-associated colon carcinogenesis at least partially by
reducing abnormal cell proliferation, inducing cellular apoptosis, and suppressing the
expression of proinflammatroy cytokines in the colon mucusa of AOM/DSS-treated mice.
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Figure 5.3 Immunostaining of Ki-67 and PCNA in colon mucosa
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Figure 5.4 Immunostaining of cleaved caspase 3 and iNOS in colon mucosa

Figure 5.5 Effects of 5DN on protein levels and mRNA levels of IL-1β and IL-6 in the
colon mucosa of AOM/DSS-treated mice
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5.3.4 Identification and quantification of colonic metabolites of 5DN in mice
The metabolic fate of dietary component is critical for their biological activities. We
and others have showed that orally administration of PMFs, including NBT, tangeretin,
and 5DN, resulted in the production of various metabolites via extensive
biotransformation(8,77,80,124). Specifically, we have identified three major metabolites
of 5DN in the urine of 5DN-fed mice as: 5,3ʹ-didemethylnobiletin (M1),
5,4ʹ-didemethylnobiletin (M2) and 5,3ʹ,4ʹ-tridemethylnobiletin (M3). Interestingly, all
these metabolites exhibited potent, even stronger effect against the growth of human lung
and colon cancer cells in culture in comparison with their parent compound 5DN(77,78).
In this study, to determine the role of biotransformation in the chemopreventive effect of
5DN against colitis-associated colon carcinogenesis, the identity and abundance of
metabolites of 5DN in the colonic mucosa need to be investigated. This is because the
metabolites, rather than 5DN itself, may be responsible for the biological activities we
observed due to their potentially stronger activities and abundance. We hypothesized that
the urinary metabolites of 5DN we identified previously will be formed in colonic
mucosa of 5DN fed mice. By conducting HPLC analysis followed by mass spectroscopy
analysis on colonic mucosa samples, we confirmed that three metabolites M1, M2, and
M3 were indeed present in the colonic mucosa of 5DN fed mice (Figure 5.6). These
results suggested that orally administration of 5DN resulted in the formation of three
major metabolites (M1, M2, and M3) in colonic mucosa of mice. The mechanism of the
transformation from 5DN to these metabolites is not clear yet. However, it is likely that
phases I and II metabolism play important role in their formation as well as
biotransformation by gut microbiome.
We further quantified the levels of 5DN and its metabolites in the mucosa samples
from 5DN-fed mice. As shown in Figure 5.6, the colonic levels of 5DN, M1, M2, and M3
were 13.6 ± 2.8, 7.8 ± 2.3, 10.2 ±1.9, and 2.8 ± 0.4 nmol/g of tissue, respectively. The
levels of M1 and M2 were similar to 5DN itself. However, the total levels of metabolites
were –fold higher than that of 5DN in the colonic mucosa. This information indicated that
the inhibitory effect of 5DN against colitis-associated colon carcinogenesis we observed
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might be at least partially attributed to its metabolites. Together for the first time, we
successfully identified M1, M2, and M3 as three major colonic metabolites of 5DN in
mice after long-term oral administration of 5DN. Most interestingly, the levels of
metabolites combined were much higher than 5DN in the colonic mucosa, suggesting the
importance of biotransformation in the biological effects of orally administered 5DN.
Figure 5.6 Representative HPLC chromatogram and quantification of 5DN, M1, M2, and
M3 in the colonic mucosa.

5.3.5 Colonic metabolites of 5DN showed stronger effects than 5DN on inhibiting
growth, inducing cell cycle arrest and apoptosis of human colon cancer cells
Due to the fact that long-term administration of 5DN resulted in the presence of 5DN
as well as abundant levels of its metabolites in the colonic mucosa, we hypothesized that
thee metabolites might played an important role in the inhibitory effects of dietary 5DN
on colitis-associated colon carcinogenesis. To confirm our hypothesis, herein we studied
the effects of 5DN and its metabolites (M1, M2, and M3) on the growth of human
HCT116 colon cancer cells. HCT116 cells were treated with serial concentrations of
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5DN(4-20 µM), M1 (0.1-0.5 µM), M2 (4-20 µM), and M3 (4-20 µM) (Figure 5.7). After
72 h of incubation, all 5 compounds significantly inhibited the growth of HCT116 cells in
dose-dependent manner. Importantly, all three metabolites of 5DN showed more potent
inhibition than 5DN. Markedly, M1 demostrated much stronger inhibitory effects than
others. M1 at only 0.5 µM inhibited cell growth by 82%, and this is stronger than those
produced by 5DN at much higher concentration (20 µM). The estimated IC50 values of
5DN, M1, M2, and M3 were 13.5, 0.22, 11.5 and 7.0 µM, respectively. It is noteworthy
that the IC50 values of all metabolites were lower than 5DN, and the IC50 value of M1
werer about 61-fold lower than that of 5DN. These higher potency of M1, M2, and M3
than 5DN suggested that they might contribute to the inhibition of colon carcinogenesis.
Figure 5.7 Growth inhibitory effects of 5DN, M1, M2, and M3 on HCT116 human colon
cancer cells

To better understand the mechanisms by which 5DN and its metabolites inhibit the
cancer cell growth, cell cycle and apoptosis analysis were conducted on cancer cells
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treated with 5DN, M1, M2 and M3 at concentration s that produced similar degree of
growth inhibition on the cells. As showed in Figure 5.8, all compounds were able to
modulated cell population distribution in different manner and intensity. 5DN at 20 µM
and M2 at 10 µM significantly increased cell population in G2/M phase, and decreased
cell population in S phase, however, M1 at only 0,25 µM, caused similar effects when
compared to 5DN and M2, suggesting a much stronger effect in inducing cell cycle arrest.
M3 at 10 µM showed same manner of cell cycle arrest as those caused by 5DN, but with
much more potency. Overall, these results showed that 5DN, M1, M2, and M3 all caused
G2/M phase cell cycle arrest with different potency, suggesting their difference in
chemical structures may lead to different molecular mechanism that be involved in the
action.
Figure 5.8 Effects of 5DN, M1, M2, and M3 on cell cycle progression and apoptosis of
HCT116 cells.
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Triggering apoptosis in cancer cells is one of the effective strategies in cancer
chemoprevention. To determine if apoptosis contributed to the growth inhibition of 5DN
and its metabolites on colon cells, the Annexin-V/PI double staining assay was conducted
by using flow cytometry. As shown in Figure 5.7, after 48 h of treatment, compared to
control cells, both early and late apoptotic cell populations were significantly increased
by all four compounds in HCT116 cells. Importantly, all three metabolites, especially M1,
showed much stronger effects than 5DN. For instance, treatment with 5DN at 20 µM
increased early apoptotic cell population by 7.6-fold compared to the control. M1 at only
0.25 µM also increased early apoptotic cell population by 7.6-fold, and M3 at 10 µM,
which is half dose of 5DN, increased 11.8-fold of early apoptotic cell population
compared to control. These results demonstrated that 5DN and its metabolites, especially
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M1 caused significant apoptosis in human colon cancer cells. And the stronger effects
produced by the metabolites also indicated that they might play important roles in
inhibiting colon carcinogenesis by inducing apoptosis.
5.3.6 5DN and its colonic metabolites modulated key signaling proteins related to
cell proliferation and apoptosis
To better understand the molecular mechanisms underlying the inhibitory effects
produced by 5DN and its colonic metabolites on colon cancer cells, we investigated their
effects on the expression of key signaling proteins related to cell cycle and apoptosis
pathways in HCT116 cells by immunoblotting analysis. Cell cycle related proteins were
analyzed after 24 h of treatment, and apoptotsis related proteins were analyzed after 48 h
of treatment. As shown in Figure 5.8, 5DN and all three colonic metabolites significant
increased of p21Cip1/Waf1 and p27 expressions. However, all the metabolites, especially M3
at 10 µM decreased the expression levels of Cyclin A2, Cyclin B1 and phosphorylated
Cyclin B1Ser147. The loss of normal cell proliferation caused by abnormal regulation of
cell cycle is one of the hallmarks of cancer. Cyclins, cyclin dependent kinases (CDKs),
and CDK inhibitors play important roles in regulating cell cycle progression. The
formation of Cyclin/CDK complexes drives the cell cycle transition, while CDK
inhibitors induced cell cycle arrest(200). We found that the metabolites, especially M3,
decreased the expressions of Cyclin A2, Cyclin B1 and phosphorylated Cyclin B1Ser147,
which at least in part, led to cell accumulation in G2/M phase. The complex of
CyclinB1/Cdc2 and the activation of this complex by the phosphorylation of Cyclin B1
are mandatory for a cell to enter into mitosis at G2/M transition(201). Since Cyclin A is
thought be involved in the activation and stabilization of cyclin B/CDK1 complex(202),
so the decreased Cyclin A expression caused by the metabolites may at least in part
decrease the activation of Cyclin B1, which further led to cell accumulation in G2/M
phase. p21Cip1/Waf1 is a negative CDK regulator that can be directly bound to the cyclin
B1/Cdc 2 complex and inhibit its activity, which further blocks cell in the G2/M
phase(134)(203). In addition, p21Cip1/Waf1 can diminish Cdc2 protein levels by decreasing
Cdc2 mRNA transcrptions and its promoter activity(204). p53 is a tumor suppressor that
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plays important roles in inhibiting carcinogenesis by inducing cell cycle arrest(134),
cellular apoptosis(135), and DNA repair(136). Increased expression of p53 can result in
G2/M cell cycle arrest by decreasing expression of both cyclin B1 and Cdc2(134,137).
Moreover, the expression of p21Cip1/Waf1 is under transcriptional control by the p53 tumor
suppressor gene. 5DN and all its colonic metabolites significantly increased the
expression of p53, which may contribute to the cell cycle arrest in G2/M phase.
Figure 5.9 Effects of 5DN, M1, M2, and M3 on cell cycle and apoptosis-related
signaling proteins in HCT116 human colon cancer cells.
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The evasion of apoptosis is considered to facilitate the development of various
cancer(205). The central engines of apoptosis are the caspases, cascades of cysteine
aspartyl proteases that implement cell death by cleaving a variety of intracellular
substrates that trigger programmed cell death.The activation (cleavage) of caspase-9
results in the activation its downstream effector caspase-3, which further triggering
cellular apoptosis. The activation (cleavage) of caspe-3 can also lead to the activation of
other key effectors, such like PARP, which can ultimately promote apoptosis by
interfering chromatin condensation and DNA fragmentation(144). Our results (Figure 5.9)
showed that 5DN and its colonic metabolites strongly activate the caspase cascade by
cleavage of caspase-9, capase-7 caspase-3, and their final protein target PARP in HCT116
cells. And this may be driven by the upregulation of p53. Moreover, the metabolites,
especially M1 at only 0.25 µM and M3 at 10 µM, showed more potent effects. These
findings demonstrated that the induction of apoptosis by 5DN and its metabolites play
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important role in the inhibition of colon carcinogenesis.
5.4 Conclusion
In conclusion, this study demonstrated that dietary 5DN significantly inhibited
colitis-associated colon carcinogenesis in AOM/DSS-treated CD-1 mice. For the first
time, we identified and quantified the major colonic metabolites of 5DN in the colonic
mucosa

of

5DN

fed

mice,

namely

5,3ʹ-didemethylnobiletin

(M1),

5,4ʹ-didemethylnobiletin (M2) and 5,3ʹ,4ʹ-tridemethylnobiletin (M3). The level of each
metabolite is similar as 5DN in mucosa, and the total amount of metabolites is much
higher than 5DN. We further demonstrated that the colonic metabolites of 5DN showed
stronger anticancer effects than 5DN, which was evidenced by their superior effects in
inhibiting HCT116 human colon cancer cell growth, inducing cell cycle arrest and
apoptosis, and modulating key signaling protein related to cell proliferation and apoptosis.
Together, our results suggested that the chemopreventive effects of dietary 5DN against
colitis-associated colon carcinogenesis were closely associated with its colonic
metabolites.
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CHAPTER 6
CONCLUDING REMARKS
Cancer is still regarded as one of the most diagnosed and fatal diseased worldwide.
At present, lung cancer and colon cancer are the most leading cause and the second
leading cause of cancer death among all type of cancer in the US, respectively.
Traditional cancer treatments or therapies (such like surgery, chemotherapy or
radiotherapy) have been shown serious side effects, complications, and expensive cost,
especially long-term treatment. Therefore, chemoprevention by phytochemicals or
nutraceuticals has gained much attention in the cancer research because of their
pleiotropic effects and relatively non-toxic behavior. Biotransformation plays crucial
roles in the health-benefit effects of bioactive compounds because they are undergone
diverse reaction after oral ingestion.
In

this

thesis,

the

in

vivo

and

in

vitro

chemopreventive

effects

of

5-Demethylnobiletin (5DN) and its metabolites on lung carcinogenesis were
demonstrated. Our results clearly showed that the oral administration of 5DN
significantly inhibited lung tumorigenesis in NNK-treated mice. Two major metabolites
of 5DN were identified and quantified in lung tissues of 5DN-fed mice. We further
demonstrated that these metabolites, especially 5,3ʹ-didemethylnobiletin (M1), had
significant stronger anticancer effects than 5DN itself, which was evidenced by their
superior inhibitory activities on human and mouse lung cancer cell growth, introduction
of cell cycle arrest and cellular apoptosis and modulation of key regulatory signaling
proteins.

Taking together, our results demonstrated that the chemopreventive effects of

dietary 5DN against lung carcinogenesis were strongly associated with its metabolites.
Combination of different bioactive agents may enhance their protective effect
against cancer due to the their synergistic interaction. Our results showed that nobiletin
(NBT)/atorvastatin (ATST) combination at lower dose produced much stronger inhibition
on NNK-induced lung carcinogenesis in mice than those produced by NBT or ATST
alone at higher doses. And this enhanced effect was considered to be synergistic which
confirmed by isobologram analysis, which provided a rationale for combining NBT and
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ATST as a new cancer treatment and prevention strategy.
Inflammation greatly promotes the development of colon carcinogenesis. We
demonstrated that dietary 5DN significantly inhibited colitis-associated colon
carcinogenesis in AOM/DSS-treated CD-1 mice. We identified and quantified the major
colonic metabolites of 5DN in the colonic mucosa of 5DN fed mice. The level of each
metabolite is similar as 5DN in mucosa, and the total amount of metabolites is much
higher than 5DN. The colonic metabolites of 5DN showed stronger anticancer effects
than 5DN, which was evidenced by their superior effects in inhibiting HCT116 human
colon cancer cell growth, inducing cell cycle arrest and apoptosis, and modulating key
signaling protein related to cell proliferation and apoptosis. Together, our results
suggested that the chemopreventive effects of dietary 5DN against colitis-associated
colon carcinogenesis were closely associated with its colonic metabolites. The
dissertation presented here provides solid scientific evidence of the health promoting
activities of PMFs and encourages future clinical studies, as well as nutraceutical and
pharmaceutical research.
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